var title_f1_19_1328="Angioplasty in RA stenosis";
var content_f1_19_1328=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F67188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F67188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Percutaneous transluminal renal angioplasty for renal artery stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Renal arteriogram after percutaneous transluminal renal angioplasty (PTRA) has largely corrected the stenotic lesion in the right renal artery (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Rose BD. Pathophysiology of Renal Disease, 2d ed, McGraw-Hill, New York 1987.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_19_1328=[""].join("\n");
var outline_f1_19_1328=null;
var title_f1_19_1329="Influenza pneumonia CT";
var content_f1_19_1329=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Influenza virus pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 415px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Influenza virus pneumonia. High-resolution computed tomography scan in a 34-year-old man who developed influenza virus pneumonia following hematopoietic stem cell transplantation shows small foci of consolidation, patchy ground-glass opacities, and a few centrilobular nodules in the right lower lobe. Also noted are postoperative changes related to previous right upper lobectomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Infections. In: High-resolution CT of the lung, 4th Ed, Webb WR, M&uuml;ller NL, Naidich DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_19_1329=[""].join("\n");
var outline_f1_19_1329=null;
var title_f1_19_1330="Patient information: Scabies (The Basics)";
var content_f1_19_1330=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15464\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/16/41218\">",
"         Parts of the body affected by scabies",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/58/4000\">",
"          Scabies between the fingers",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?18/18/18721\">",
"         Patient information: Scabies (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Scabies (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/scabies-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H480923689\">",
"      <span class=\"h1\">",
"       What is scabies?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Scabies is a condition that makes your skin very itchy. It happens when tiny insects called mites burrow under your skin to lay their eggs.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H480923696\">",
"      <span class=\"h1\">",
"       How did I get scabies?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You probably caught scabies from someone else who has it. The condition spreads easily between people who are in close contact. It is also possible to catch scabies from the clothes of someone with the condition.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H480923703\">",
"      <span class=\"h1\">",
"       Are there symptoms besides itching?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The main symptom is itching, but there are other symptoms. People with scabies usually get little red bumps or blisters on their skin (",
"      <a class=\"graphic graphic_picture graphicRef54705 \" href=\"UTD.htm?3/58/4000\">",
"       picture 1",
"      </a>",
"      ). Sometimes the bumps are hard to see. Some people even notice tiny tunnels in their skin where the mites have buried themselves.",
"     </p>",
"     <p>",
"      These are the body parts that are most often affected by scabies (",
"      <a class=\"graphic graphic_figure graphicRef79896 \" href=\"UTD.htm?40/16/41218\">",
"       figure 1",
"      </a>",
"      ):",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The fingers and webbing between the fingers",
"       </li>",
"       <li>",
"        The skin folds around the wrists, elbows, and knees",
"       </li>",
"       <li>",
"        The armpits",
"       </li>",
"       <li>",
"        The area around the nipples (especially in women)",
"       </li>",
"       <li>",
"        The waist",
"       </li>",
"       <li>",
"        The penis and scrotum (in men)",
"       </li>",
"       <li>",
"        The lower buttocks and upper thighs",
"       </li>",
"       <li>",
"        The sides and bottoms of the feet",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H480923710\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, see your doctor or nurse. If you have scabies, he or she can give you medicine to get rid of it. Scabies is hard to get rid of. And you can get infections if you keep scratching at it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H480923717\">",
"      <span class=\"h1\">",
"       How is scabies treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse can give you a prescription for a medicine that kills the mites that cause scabies. A medicine that is often used is called",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?30/6/30821?source=see_link\">",
"       permethrin",
"      </a>",
"      . It is also sold with the brand name Elimite&reg; or Acticin&reg;.",
"     </p>",
"     <p>",
"      The scabies medicine comes in a cream or lotion that you put on your skin. You must use the medicine exactly how the doctor or nurse tells you to. Otherwise it may not work.",
"     </p>",
"     <p>",
"      If you are being treated for scabies, the doctor or nurse will probably want the people who live with you to be treated, too. They might be carrying the mite that causes scabies, even if they have no symptoms.",
"     </p>",
"     <p>",
"      When you start treatment, wash all the clothes you and others in your home wore in the last 4 to 5 days in hot water. Then dry them in a dryer on high heat. You should also wash any bedclothes (sheets and blankets) or towels people in your home have touched. If your child is getting treated, wash his or her stuffed animals, too. Dry-cleaning will also get rid of the scabies mite. Any bedding, clothing, or towels that you cannot wash or dry-clean should be placed in a sealed plastic bag for at least 3 days. Scabies mites usually die without contact with human skin after a few days.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H480923724\">",
"      <span class=\"h1\">",
"       What can I do to stop the itching?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can take medicines called antihistamines. These are the medicines people often take for allergies.",
"     </p>",
"     <p>",
"      Itching can last for several weeks, even after the scabies mite is gone. Your doctor or nurse may suggest you use a cream with a medicine called a steroid to help with the itching. (These are not the same steroids that athletes take to build up muscle.) These steroids relieve itching and swelling.",
"      <br/>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H480923731\">",
"      <span class=\"h1\">",
"       When can my child go back to school?",
"      </span>",
"      &nbsp;&mdash;&nbsp;He or she can go back to school after one day of treatment with",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?30/6/30821?source=see_link\">",
"       permethrin",
"      </a>",
"      .",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H480923738\">",
"      <span class=\"h1\">",
"       Some people get a severe kind of scabies",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with HIV or AIDS, cancer, or other conditions can get a severe type of scabies called \"crusted scabies.\" Crusted scabies causes large, crusty red patches or bumps to form on the skin. It spreads more easily than regular scabies. People with crusted scabies often get it on their head, hands, and feet. They sometimes need to take pills to get rid of scabies.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H480923745\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/18/18721?source=see_link\">",
"       Patient information: Scabies (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?1/19/1330?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15464 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-B6AD6E7C64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_19_1330=[""].join("\n");
var outline_f1_19_1330=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480923689\">",
"      What is scabies?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480923696\">",
"      How did I get scabies?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480923703\">",
"      Are there symptoms besides itching?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480923710\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480923717\">",
"      How is scabies treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480923724\">",
"      What can I do to stop the itching?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480923731\">",
"      When can my child go back to school?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480923738\">",
"      Some people get a severe kind of scabies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H480923745\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15464\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/16/41218\">",
"      Parts of the body affected by scabies",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/58/4000\">",
"       Scabies between the fingers",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/18/18721?source=related_link\">",
"      Patient information: Scabies (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_19_1331="Bladder neck exposed";
var content_f1_19_1331=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bladder neck exposed during radical vulvectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_19_1331=[""].join("\n");
var outline_f1_19_1331=null;
var title_f1_19_1332="Acetic acid, propylene glycol diacetate, and hydrocortisone: Patient drug information";
var content_f1_19_1332=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Acetic acid, propylene glycol diacetate, and hydrocortisone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/25/34194?source=see_link\">",
"     see \"Acetic acid, propylene glycol diacetate, and hydrocortisone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F129903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Acetasol&reg; HC;",
"     </li>",
"     <li>",
"      VoSol&reg; HC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691827",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat ear infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701431",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to acetic acid, propylene glycol, hydrocortisone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Chickenpox, herpes infection, ruptured ear drum, or smallpox-like virus.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ear discomfort.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699026",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad ear pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the ear only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lie on your side with problem ear up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pull the outer ear outward and upward.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put drops in ear without touching dropper to ear. Stay on side for 2 minutes or put cotton plug in ear.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694868",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow what is given to you by your doctor for using the wick.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11466 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-91.202.164.29-FFA7B79098-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_19_1332=[""].join("\n");
var outline_f1_19_1332=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129903\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023269\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023268\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023273\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023274\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023276\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023271\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023272\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023277\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023278\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/25/34194?source=related_link\">",
"      Acetic acid, propylene glycol diacetate, and hydrocortisone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_19_1333="Breastfeeding guide";
var content_f1_19_1333=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Breastfeeding guide (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?1/19/1333/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/19/1333/contributors\" id=\"au4693\">",
"       Richard J Schanler, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/19/1333/contributors\" id=\"au1765\">",
"       Lisa Enger, RN, BSN, IBCLC",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?1/19/1333/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/19/1333/contributors\" id=\"se4702\">",
"       Steven A Abrams, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?1/19/1333/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/19/1333/contributors\" id=\"de7255\">",
"       Melanie S Kim, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?1/19/1333?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Human milk is widely recognized as the optimal source of nutrition for all infants. Breast milk promotes development of the infant's immune system and meets the nutritional needs of a full-term infant until approximately six months of age, when complementary foods and fluids are usually added to the diet. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/32/41476?source=see_link\">",
"      \"Patient information: Starting solid foods during infancy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Most national and international groups recommend",
"     <strong>",
"      exclusive",
"     </strong>",
"     breastfeeding without the use of infant formula or other foods or liquids for the first six months, and partial breastfeeding for at least 12 months. Despite the overwhelming evidence in favor of breastfeeding, in the United States, only about 70 percent of women breastfeed immediately after birth and only about 30 percent of women are still breastfeeding at six months. There are many reasons that women choose not to breastfeed, including embarrassment, lack of knowledge about the benefits of breast milk, belief that formula is equal to breast milk, and myths about the \"ease\" of formula feeding compared to breastfeeding.",
"    </p>",
"    <p>",
"     This topic discusses how to breastfeed, including positioning, latch on, frequency and length of feeding, pacifiers, and the need for supplements and vitamins. Additional breastfeeding topics are available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"      \"Patient information: Deciding to breastfeed (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/54/31588?source=see_link\">",
"      \"Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/61/37845?source=see_link\">",
"      \"Patient information: Common breastfeeding problems (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/25/17813?source=see_link\">",
"      \"Patient information: Breast pumps (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHEN TO START BREASTFEEDING",
"     </span>",
"    </p>",
"    <p>",
"     Breastfeeding should begin within the first few hours of delivery, if possible, by allowing the baby to rest or nurse, skin-to-skin, on the mother's chest. During this time, most infants are alert and interested in nursing. However, there is no evidence that it will be more difficult or impossible to breastfeed if the infant cannot nurse within this time period.",
"    </p>",
"    <p>",
"     In some situations, the infant or mother must be separated for several hours or even days after delivery. Pumping the breasts and then storing the milk for use is recommended to stimulate production of breast milk; this can be started as soon as it is safe, optimally within the first six hours after delivery. A separate topic is available that discusses the use of breast pumps. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/25/17813?source=see_link\">",
"      \"Patient information: Breast pumps (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     In the first few days after delivery, the woman produces a small amount of a yellowish milk called colostrum. Colostrum is rich in nutrients and provides all the calories a baby needs for the first few days.",
"    </p>",
"    <p>",
"     Many women worry that their infant is not getting enough milk immediately after delivery, when only small amounts of colostrum are normally produced. Infants are born with an excess of fluid and sugar stores that they are able to use as the woman's milk supply increases.",
"    </p>",
"    <p>",
"     It is normal to produce small amounts of milk in the beginning. With continued frequent breastfeeding, a larger amount of mature milk will be produced within two or three days. Infants normally lose weight during the first few days of life and gradually regain this weight by two weeks after delivery.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      POSITIONING",
"     </span>",
"    </p>",
"    <p>",
"     A woman may use one of several positions to hold her infant while breastfeeding. There is no one \"best\" position for every infant and woman; the best position is one that is comfortable for the woman and allows the infant to latch-on, suckle, and swallow easily. A woman may have several preferred positions depending upon the baby's size, the baby or mother's medical condition(s), and feeding location (eg, in bed versus in a chair).",
"    </p>",
"    <p>",
"     In all positions, the baby should not have to turn his or her head to nurse; the baby's nose should be aligned with the mother's nipple (",
"     <a class=\"graphic graphic_figure graphicRef69241 \" href=\"UTD.htm?40/62/41967\">",
"      figure 1",
"     </a>",
"     ). Turning the head in any direction makes it more difficult to coordinate suckling and swallowing, and can potentially make it more difficult for the baby to latch correctly. (See",
"     <a class=\"local\" href=\"#H8\">",
"      'Latch on'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     Pillows or nursing supports can help to ensure that both the woman and the infant are comfortable. When the mother is sitting in a chair, a foot stool or ottoman is helpful in supporting the infant's weight and preventing fatigue in the mother's arms, shoulders, and neck.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Cradle hold",
"     </span>",
"     &nbsp;&mdash;&nbsp;The cradle hold can be done while the mother sits in a chair. To feed from the left breast, the infant's head and body are supported by the mother's left forearm (",
"     <a class=\"graphic graphic_figure graphicRef69936 \" href=\"UTD.htm?40/55/41855\">",
"      figure 2",
"     </a>",
"     ). The mother's left hand usually supports the baby's buttocks or upper thighs. Some women use a pillow to support this arm. The baby's stomach should be flat against the mother's chest and the baby's head should be in line with the body (not turned). The mother's free hand (the right hand in this example) supports and guides the breast to the infant's wide open mouth. The thumb on the free hand may be placed on top of the areola and the breast supported with the cupped fingers. Care should be taken to position the hand away from the nipple so that the thumb and fingers do not interfere with latching.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Cross-cradle hold",
"     </span>",
"     &nbsp;&mdash;&nbsp;The cross-cradle hold can also be done while the mother sits in a chair. To feed from the left breast, the infant's head and body are supported by the mother's right hand and forearm. Some women use a pillow to support this arm (",
"     <a class=\"graphic graphic_figure graphicRef71940 \" href=\"UTD.htm?32/12/32975\">",
"      figure 3",
"     </a>",
"     ). The baby's stomach should be flat against the mother's chest and the baby's head should be in line with the body (not turned). The mother's free hand (the left hand in this example) supports and guides the breast to the infant's wide open mouth. The thumb on the free hand may be placed on top of the areola and the breast supported with the cupped fingers. Care should be taken to position the hand away from the nipple so that the thumb and fingers do not interfere with latching.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Football hold",
"     </span>",
"     &nbsp;&mdash;&nbsp;The football position allows a woman to easily see the baby at her breast. It is often preferred by women who have an abdominal incision, after a Cesarean section, or by women with large breasts or a small or premature baby. The baby is supported by a pillow as the mother sits, which should allow the baby's head to be at the level of the mother's breast.",
"    </p>",
"    <p>",
"     To feed from the left breast, the baby's body and legs are under the left arm, with the head supported with the mother's left hand (",
"     <a class=\"graphic graphic_figure graphicRef70124 \" href=\"UTD.htm?32/43/33471\">",
"      figure 4",
"     </a>",
"     ). The mother's free hand (the right hand in this example) supports and guides the breast to the infant's wide-open mouth.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Side-lying hold",
"     </span>",
"     &nbsp;&mdash;&nbsp;The side-lying hold allows the mother to nurse while lying down. When using this position, there should be no excess bedding around the infant. The side-lying hold should not be used on a waterbed, a couch, or a recliner because this poses a suffocation hazard to the infant.",
"    </p>",
"    <p>",
"     To nurse from the left breast, the woman lies on her left side. The baby's head and body lie parallel to the woman's body, with the baby's mouth close to and facing the woman's left breast (",
"     <a class=\"graphic graphic_figure graphicRef71497 \" href=\"UTD.htm?25/50/26400\">",
"      figure 5",
"     </a>",
"     ). The woman may prefer to have a pillow under her head, with her left hand between her head and the pillow. The mother's free hand (the right hand in this example) supports and guides the breast to the infant's wide open mouth. The thumb on the free hand may be placed on top of the areola and the breast supported with the cupped fingers. Care should be taken to position the hand away from the nipple so that the thumb and fingers do not interfere with latching.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28456993\">",
"     <span class=\"h2\">",
"      Laid back or &ldquo;biological nursing&rdquo;",
"     </span>",
"     &nbsp;&mdash;&nbsp;In the laid back or &ldquo;biological nursing&rdquo; position, the mother is semi-reclined with her arms and torso well supported, and the baby is placed on her stomach between the mother&rsquo;s breasts [",
"     <a class=\"abstract\" href=\"UTD.htm?1/19/1333/abstract/1\">",
"      1",
"     </a>",
"     ]. In this position, mothers are more comfortable and their infants are able to latch more easily as the baby is securely positioned against the mother&rsquo;s body and the baby&rsquo;s reflexes assist in latching on. Mothers also may find that they do not have to work as hard supporting their infants and tire less.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      LATCH ON",
"     </span>",
"    </p>",
"    <p>",
"     Latching on refers to the infant's formation of a tight seal around the nipple and most of the areola with his or her mouth. A correct latch-on allows the infant to obtain an adequate amount of milk and helps to prevent nipple soreness and trauma.",
"    </p>",
"    <p>",
"     Signs of a good latch-on include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The top and bottom lips should be open to at least 120&ordm; (",
"       <a class=\"graphic graphic_figure graphicRef69241 \" href=\"UTD.htm?40/62/41967\">",
"        figure 1",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       The lower lip (and, to a lesser extent, the upper lip) should be turned outward against the breast",
"      </li>",
"      <li>",
"       The chin should be touching the breast while the nose should be close to the breast",
"      </li>",
"      <li>",
"       The cheeks should be full",
"      </li>",
"      <li>",
"       The tongue should extend over the lower lip during latch-on remain below the areola during nursing (visible if the lower lip is pulled away)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     When an infant is latched correctly, the woman may feel discomfort for the first 30 to 60 seconds, which should then decrease. Continued discomfort may be a sign of a poor latch-on. To prevent further pain or nipple trauma, the woman should insert her clean finger into the infant's mouth to break the seal. She can then reposition the infant and assist with latch-on again. Information about painful or sore nipples is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/61/37845?source=see_link\">",
"      \"Patient information: Common breastfeeding problems (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Signs of poor latch-on include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       The upper and lower lip are touching at the corners of the mouth",
"      </li>",
"      <li>",
"       The cheeks are sunken",
"      </li>",
"      <li>",
"       Clicking sounds are heard, corresponding to breaking suction",
"      </li>",
"      <li>",
"       The tongue is not visible below the nipple (if the lower lip is pulled down)",
"      </li>",
"      <li>",
"       The nipple is creased after nursing",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     A video that describes how to latch a baby correctly is available online at",
"     <span class=\"nowrap\">",
"      www.ameda.com/resources/video.",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Suckling and swallowing",
"     </span>",
"     &nbsp;&mdash;&nbsp;An infant must be able to suckle and swallow correctly to consume an adequate amount of milk. It should be possible to hear the infant swallow. These early swallows may sound like the letter \"C\" in cat. The infant's jaw should move quickly to start the flow of milk, with a swallow heard after every one to three jaw movements [",
"     <a class=\"abstract\" href=\"UTD.htm?1/19/1333/abstract/2\">",
"      2",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      FREQUENCY AND LENGTH OF FEEDING",
"     </span>",
"    </p>",
"    <p>",
"     Women are encouraged to attempt breastfeeding as soon as the infant begins to show signs of hunger. Early signs of hunger include awakening, searching for the breast (called rooting), or sucking on the hands, lips, or tongue. Most infants do not cry until they are very hungry; waiting to breastfeed until an infant cries is not recommended.",
"    </p>",
"    <p>",
"     In the first one to two weeks, most infants will breastfeed 8 to 12 times per day. Some infants will want to nurse frequently, as often as every 30 to 60 minutes, while others will have to be awakened and encouraged to nurse. A baby may be awakened by changing the diaper or tickling the feet. During the first week of life, most clinicians encourage parents to wake a sleeping infant to nurse if four hours have passed since the beginning of the previous feeding. Some babies will cluster feed, meaning that they feed very frequently for a number of feedings and then sleep for a longer period.",
"    </p>",
"    <p>",
"     Caring for an infant can be an exhausting experience. However, it may be comforting to know that breastfeeding is no more time consuming than formula feeding, which often requires additional time to purchase and prepare the formula and wash bottles and nipples.",
"    </p>",
"    <p>",
"     The length of time an infant needs to finish breastfeeding varies, especially in the first few weeks after delivery; some infants require as little as five minutes while others need 20 minutes or more. Most experts recommend that the infant be allowed to actively breastfeed for as long as desired; timing the feeding (ie, watching the clock) is not recommended. \"Active\" breastfeeding means that the infant is regularly suckling and swallowing.",
"    </p>",
"    <p>",
"     It is not necessary to switch sides in the middle of a nursing session. Thorough emptying of one breast allows the baby to consume hind milk, which has a higher fat content than milk available at the start of a nursing session.",
"    </p>",
"    <p>",
"     Most infants signal that they are finished nursing by releasing the nipple and relaxing the facial muscles and hands. Infants younger than two to three months often fall asleep during nursing, even before they are finished. In this case, it is reasonable to try and awaken the child and encourage them to finish nursing. After finishing one breast, offer the other side with the understanding that the infant (especially an older infant) may not be interested.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Growth spurts",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is common for an infant to occasionally nurse more frequently or for longer periods during the first year. However, every infant is different, and increases in appetite may occur at different times. Parents are encouraged to allow their infant to nurse more frequently when the infant shows interest.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      How much is enough?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many parents are concerned that their infant is not getting enough milk because it is not possible to see how much milk the baby consumes. There are a few clues that parents can use to estimate whether the baby is getting enough breast milk.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Monitor diapers",
"     </span>",
"     &nbsp;&mdash;&nbsp;Keep a written record of the number of wet and dirty diapers per day. Many parents keep a written record of wet and dirty diapers for the first week or two.",
"    </p>",
"    <p>",
"     Normally, by the fourth to fifth day after birth, an infant should have at least six wet diapers per day with clear or pale yellow urine. Fewer than six wet diapers, or dark yellow or orange urine in the diaper are signs of inadequate intake and should be reported to the child's clinician.",
"    </p>",
"    <p>",
"     Meconium is the sticky dark-colored stool that infants normally produce for the first few days after birth. An infant's stool should become mustard yellow to light brown, often with visible milk curds, by the fourth to fifth day. Most infants have four or more stools per day by day four.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Monitor weight",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is normal for infants to lose weight after delivery, with the average infant losing four to five ounces within the first few days of life. Normally, infants stop losing weight by five days of age and typically regain their birth weight by one to two weeks of age.",
"    </p>",
"    <p>",
"     Infants who lose more than this amount may be at risk for becoming dehydrated",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     developing jaundice. If this occurs, the healthcare provider will try to determine the cause of the infant's weight loss and whether supplementation with banked human milk, pumped milk, or infant formula is needed. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/45/16083?source=see_link\">",
"      \"Patient information: Jaundice in newborn infants (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The American Academy of Pediatrics recommends that all healthy breastfeeding newborns are weighed and examined by a healthcare provider three to five days after birth and again two to three weeks after birth; this allows the provider to monitor for signs of jaundice, dehydration, weight loss, or other complications, and to answer parents' questions.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Maintaining milk supply",
"     </span>",
"     &nbsp;&mdash;&nbsp;Milk continues to be produced in the breast based upon how frequently and thoroughly milk is removed. Regularly nursing an infant triggers the release of two hormones, prolactin and oxytocin. Milk production is reduced if milk is not removed regularly or if the breast is incompletely emptied. In addition, the breasts are more likely to become uncomfortably full and leak milk if a feeding is delayed or skipped.",
"    </p>",
"    <p>",
"     For this reason, breastfeeding women are encouraged to nurse their baby as often as the baby shows signs of hunger. Most experts recommend allowing the baby to nurse until finished with one side, then switching to the other side. (See",
"     <a class=\"local\" href=\"#H10\">",
"      'Frequency and length of feeding'",
"     </a>",
"     above.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      PACIFIERS",
"     </span>",
"    </p>",
"    <p>",
"     Parents often use a pacifier to soothe their infant, although pacifiers should not be used to delay feedings. If an infant appears hungry he or she should be offered the breast. If parents desire to use a pacifier, pacifiers should not be introduced until breastfeeding is well established usually around two weeks of age.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      IS BREAST MILK ALL MY BABY NEEDS?",
"     </span>",
"    </p>",
"    <p>",
"     It is not necessary to give formula, bottled water, or glucose water supplements to a full term infant who gains weight appropriately and who has an adequate number of wet and dirty diapers. Providing formula can potentially reduce a woman's supply of breast milk, especially if formula is given in place of breastfeeding (eg, before bedtime or during the night).",
"    </p>",
"    <p>",
"     Even in hot climates, parents do not need to give water or fruit juice to a breastfed infant until he or she is approximately six months old.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Nutritional supplements",
"     </span>",
"     &nbsp;&mdash;&nbsp;A vitamin or mineral supplement may be recommended for some full-term breastfeeding infants. Nutritional supplements are usually given as a liquid with a medicine dropper or mixed into pumped breast milk.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h3\">",
"      Vitamin B12",
"     </span>",
"     &nbsp;&mdash;&nbsp;The body requires a source of vitamin B12 to maintain blood cells. Low levels of vitamin B12 can lead to anemia, developmental delay, and other problems. A multivitamin supplement that includes B12 is recommended for breastfeeding infants of strict vegetarian (vegan) mothers. Adequate B12 is available in most non-prescription infant vitamin drops.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h3\">",
"      Vitamin D",
"     </span>",
"     &nbsp;&mdash;&nbsp;The body requires vitamin D to absorb calcium and phosphorus, which are essential in the formation of bones. Inadequate levels of vitamin D in children can lead to a condition known as rickets, which causes bones to be fragile and to break easily.",
"    </p>",
"    <p>",
"     Breast milk contains vitamin D, although usually not in adequate amounts to meet an infant's needs. The only other source of vitamin D for exclusively breastfed infants is sunlight. However, the potential risk of sunburn is greater than the potential benefit of sun exposure, especially considering that a safe source of vitamin D is available.",
"    </p>",
"    <p>",
"     All breastfed infants should be given a supplement containing 400 IU of vitamin D per day, starting within days of birth.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h3\">",
"      Iron",
"     </span>",
"     &nbsp;&mdash;&nbsp;Iron is an essential nutrient that the body requires to produce and maintain red blood cells. Infants with a low iron level are at risk for a number of problems, including a low blood count (anemia). Iron deficiency has also been associated with mild impairment of the immune system and developmental delays. Breast milk contains iron that is easily absorbed. Exclusively breastfed infants who are preterm or low-birth weight are usually given a multivitamin supplement that contains iron. Specific recommendations about an infant's iron needs should be discussed with the child's healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H24\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our Web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H365489\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H365496\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/43/17075?source=see_link\">",
"      Patient information: Breastfeeding (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/19/38194?source=see_link\">",
"      Patient information: Deciding to breastfeed (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/62/22498?source=see_link\">",
"      Patient information: Jaundice in babies (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/13/7379?source=see_link\">",
"      Patient information: Health and nutrition for women who breastfeed (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/22/36194?source=see_link\">",
"      Patient information: Breast pumps (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/27/4531?source=see_link\">",
"      Patient information: Weaning from breastfeeding (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/44/1732?source=see_link\">",
"      Patient information: Having twins (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H365509\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/32/41476?source=see_link\">",
"      Patient information: Starting solid foods during infancy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"      Patient information: Deciding to breastfeed (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/54/31588?source=see_link\">",
"      Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/61/37845?source=see_link\">",
"      Patient information: Common breastfeeding problems (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/25/17813?source=see_link\">",
"      Patient information: Breast pumps (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/45/16083?source=see_link\">",
"      Patient information: Jaundice in newborn infants (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H365521\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42616?source=see_link\">",
"      Breastfeeding: Parental education and support",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17658?source=see_link\">",
"      Common problems of breastfeeding and weaning",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link\">",
"      Infant benefits of breastfeeding",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43864?source=see_link\">",
"      Maternal nutrition during lactation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/36/6727?source=see_link\">",
"      Nutritional composition of human milk for full-term infants",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=see_link\">",
"      Principles of medication use during lactation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17304?source=see_link\">",
"      The impact of breastfeeding on the development of allergic disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38745?source=see_link\">",
"      Use of psychotropic medications in breastfeeding women",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Center for Disease Control and Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/breastfeeding\">",
"      www.cdc.gov/breastfeeding",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The United States Department of Health and Human Services",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.womenshealth.gov/Breastfeeding\">",
"      www.womenshealth.gov/Breastfeeding",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Pediatrics",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www2.aap.org/healthtopics/breastfeeding.cfm\">",
"      www2.aap.org/healthtopics/breastfeeding.cfm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Massachusetts Breastfeeding Coalition",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.massbfc.org/\">",
"      www.massbfc.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Breastfeeding Online",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.breastfeedingonline.com/\">",
"      www.breastfeedingonline.com",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h2\">",
"      Finding a lactation consultant",
"     </span>",
"     &nbsp;&mdash;&nbsp;Certified lactation consultants, or LCs, are available at most hospitals as well as privately, and can be an invaluable resource for instructions about breastfeeding, pumping, milk storage, and bottle-feeding breast milk. The Web sites listed below have information about finding a lactation consultant or breastfeeding counselor.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       La Leche League",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.lalecheleague.org/\">",
"      www.lalecheleague.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       International Board of Lactation Consultant Examiners",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.iblce.org/\">",
"      www.iblce.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;phone: 703-560-7330",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       International Lactation Consultant Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ilca.org/\">",
"      www.ilca.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;phone: 919-861-5577",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?1/19/1333/abstract/2-4\">",
"      2-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?1/19/1333?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     Biological nurturing. Laid back breastfeeding. file://www.biologicalnurturing.com/ (Accessed on January 21, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1333/abstract/2\">",
"      Qureshi MA, Vice FL, Taciak VL, et al. Changes in rhythmic suckle feeding patterns in term infants in the first month of life. Dev Med Child Neurol 2002; 44:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1333/abstract/3\">",
"      Section on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics 2012; 129:e827.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Global Strategy for Infant and Young Child Feeding. 2002. Available at: www.who.int/nut/documents/gs_infant_feeding_text_eng.pdf (Accessed on June 01, 2007).",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f1_19_1333=[""].join("\n");
var outline_f1_19_1333=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHEN TO START BREASTFEEDING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           POSITIONING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           LATCH ON",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           FREQUENCY AND LENGTH OF FEEDING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           PACIFIERS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           IS BREAST MILK ALL MY BABY NEEDS?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H24\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/62/41967\" title=\"figure 1\">",
"           Latch on PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/55/41855\" title=\"figure 2\">",
"           Cradle position PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/12/32975\" title=\"figure 3\">",
"           Cross cradle position PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/43/33471\" title=\"figure 4\">",
"           Seated nursing position for breastfeeding",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/50/26400\" title=\"figure 5\">",
"           Side lying position PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f1_19_1334="Enchondroma hand";
var content_f1_19_1334=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Solitary enchondroma of the hand",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 520px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Postero-anterior radiograph of the hand. Observe the large geographic area of radiolucency within the mid-diaphysis of the fifth metacarpal. Significant expansion, endosteal scalloping, bone deformity, and pathologic fracture are noted (arrows). Matrix calcification is evident.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_19_1334=[""].join("\n");
var outline_f1_19_1334=null;
var title_f1_19_1335="Resetting AVRT extrastimulus";
var content_f1_19_1335=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    Resetting of an atrioventricular reentrant tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 433px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are four surfacec ECG leads (I, II, III, and V1) and intracardiac electrograms recorded from the high right atrium (HRA), his bundle (HBE), proximal (PCS) and distal coronary sinus (DCS), and right ventricle (RV). A critically timed RV extrastimulus (S), delivered with a coupling interval of 285 ms at a time when the His bundle (H) is refractory, advances the atrial electrogram (A), which now occurs with a coupling interval of 295 ms rather than 310 ms, due to conduction using a left posterior atrioventricular accessory pathway. As a result, the tachycardia is reset, which confirms the participation of the accessory pathway in the mechanism of the tachycardia. During the premature beat, the atrial activation sequence is not altered.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Hasan Garan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_19_1335=[""].join("\n");
var outline_f1_19_1335=null;
var title_f1_19_1336="NSAIDs: Mechanism of action";
var content_f1_19_1336=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   NSAIDs: Mechanism of action",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/19/1336/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/19/1336/contributors\">",
"     Daniel H Solomon, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/19/1336/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/19/1336/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/19/1336/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/19/1336/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/19/1336/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 17,000,000 Americans use various nonsteroidal antiinflammatory drugs (NSAIDs) on a daily basis, making this class of drugs one of the most commonly used in the world. The Centers for Disease Control in the United States predicts that, with the aging of the population, there will be a significant increase in the prevalence of painful degenerative and inflammatory rheumatic conditions, leading to a parallel increase in the use of NSAIDs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sodium salicylate, discovered in 1763, was the first NSAID. Gastrointestinal toxicity (particularly dyspepsia) associated with the use of acetylsalicylic acid (ASA) led to the introduction of phenylbutazone, an indoleacetic acid derivative, in the early 1950s; this was the first non-salicylate NSAID developed for use in patients with inflammatory conditions. Phenylbutazone is a weak prostaglandin synthetase inhibitor that also induces uricosuria. It was shown to be a useful agent in patients with ankylosing spondylitis and gout. Concerns related to bone marrow toxicity, particularly in women over the age of 60, have essentially eliminated the use of this drug.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     Indomethacin",
"    </a>",
"    , another indoleacetic acid derivative, was developed in the 1960s as a substitute for phenylbutazone. The following years witnessed the development of more and more NSAIDs in an effort to enhance patient compliance (by decreasing the absolute number of pills and frequency with which they are taken each day), reduce toxicity, and increase the antiinflammatory effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8064364\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are now at least 20 different NSAIDs, from six major classes determined by their chemical structures, available for use in the United States. These drugs differ in their dose, drug interactions, and some side effects. A comparison of the drugs, organized by chemical grouping, is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef70067 \" href=\"UTD.htm?23/54/24431\">",
"     table 1",
"    </a>",
"    ). Drug interactions and side effects are discussed separately. (See",
"    <a class=\"local\" href=\"#H8064004\">",
"     'Drug interactions'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8064259\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most NSAIDs are absorbed completely, have negligible first-pass hepatic metabolism, are tightly bound to serum proteins, and have small volumes of distribution. NSAIDs undergo hepatic transformations variously by CYP-2C8, 2C9, 2C19",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    glucuronidation. Half-lives of the NSAIDs vary but in general can be divided into \"short-acting\" (less than six hours, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/36/43592?source=see_link\">",
"     ketoprofen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    ) and \"long-acting\" (more than six hours, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/38/35432?source=see_link\">",
"     meloxicam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/18/39208?source=see_link\">",
"     nabumetone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/25/9625?source=see_link\">",
"     piroxicam",
"    </a>",
"    ). Patients with hypoalbuminemia (due, for example, to cirrhosis or active rheumatoid arthritis) may have a higher free serum concentration of the drug.",
"   </p>",
"   <p>",
"    Assessment of toxicity and therapeutic response to a given NSAID must take into account the time needed to reach the steady state plasma concentration (roughly equal to three to five half-lives of the drug). The pathogenesis of symptomatic peptic ulcer disease caused by exposure to NSAIDs is mainly a consequence of systemic (post-absorptive) inhibition of gastrointestinal (GI) mucosal cyclooxygenase (COX) activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The choice of one NSAID over another should consider patient-specific risk factors for toxicity and the way in which the drug is metabolized. In older patients, for example, the possible benefit of increased compliance with longer-acting drugs is probably offset by the enhanced incidence of gastrointestinal toxicity associated with prominent enterohepatic circulation of active metabolites. NSAIDs with a short half-life and no enterohepatic circulation may be the best choices for older debilitated patients, although any use of NSAIDs would generally be avoided in such patients because of their potential toxicity in this population. In addition, all agents should be used at the lowest effective dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8064004\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAIDs can interact with numerous drugs. These include anticoagulants, antiplatelet agents, antihypertensives, calcineurin inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , diuretics, glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , selective serotonin reuptake inhibitors (SSRIs),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX), and other medications. The interaction of NSAIDs with MTX generally requires avoidance of NSAID use in patients receiving antineoplastic doses, while both may be used concurrently with standard MTX monitoring approaches in patients receiving low dose MTX (eg, for the treatment of rheumatologic disorders). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interactions may occur due to NSAID-related reduction in renal perfusion or additive hemorrhagic toxicity. Furthermore, some NSAIDs modestly inhibit CYP-2C9 (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/36/43592?source=see_link\">",
"     ketoprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/42/33440?source=see_link\">",
"     flurbiprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/38/35432?source=see_link\">",
"     meloxicam",
"    </a>",
"    ) or",
"    <span class=\"nowrap\">",
"     CYP-2C8/2D6",
"    </span>",
"    (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    )",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    glucuronidation, which may increase concentrations of drugs highly dependent on these pathways for clearance. The effects of some interactions are listed below. (See Lexi-Interact&trade; program included with UpToDate for additional information, including suggestions for management, and to check for other potential interactions.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8064062\">",
"    <span class=\"h3\">",
"     Angiotensin converting enzyme inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAIDs may attenuate the efficacy of angiotensin converting enzyme inhibitors by blocking vasodilator and natriuretic prostaglandins and potentiating hyperkalemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link&amp;anchor=H5#H5\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\", section on 'Hyperkalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8064055\">",
"    <span class=\"h3\">",
"     Low-dose aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardioprotective effect of low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    may be negated by NSAIDs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The more limited gastrointestinal toxicity of COX-2 selective agents compared with nonselective NSAIDs may be offset by concurrent use of low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8064223\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of peptic ulcer disease increases significantly when glucocorticoids are used in combination with an NSAID, compared with the use of either alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link&amp;anchor=H11#H11\">",
"     \"Major side effects of systemic glucocorticoids\", section on 'Gastrointestinal tract'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8064272\">",
"    <span class=\"h3\">",
"     SSRIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of selective serotonin reuptake inhibitors (SSRIs) in combination with NSAIDs is associated with an increased risk of gastroduodenal toxicity compared with the use of drugs from either class alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link&amp;anchor=H11#H11\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\", section on 'Risk of gastrointestinal complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8064180\">",
"    <span class=\"h3\">",
"     Warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAIDs can increase the risk of bleeding in vitamin K antagonist treated patients by multiple mechanisms including gastrointestinal toxicity, increase in the International Normalized Ratio (INR), and interference with platelet function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H18#H18\">",
"     \"Therapeutic use of warfarin\", section on 'Use of NSAIDs and antiplatelet agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a clear individual variation in response to NSAIDs; some patients seem to respond better to one drug than to others. The risk of adverse events also seems to be variable among individual drugs and patients. These differences have been ascribed to differences in absorption, distribution, and metabolism. In addition, numerous mechanisms of action have been ascribed to the NSAIDs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cyclooxygenase inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary effect of NSAIDs is to inhibit cyclooxygenase (prostaglandin synthase), thereby impairing the ultimate transformation of arachidonic acid to prostaglandins, prostacyclin, and thromboxanes (",
"    <a class=\"graphic graphic_figure graphicRef66146 \" href=\"UTD.htm?33/29/34269\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/1\">",
"     1",
"    </a>",
"    ]. The extent of enzyme inhibition varies among the different NSAIDS, although there are no studies relating the degree of cyclooxygenase inhibition with antiinflammatory efficacy in individual patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     COX enzymes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two related isoforms of the cyclooxygenase (COX) enzyme have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]: COX-1 (PGHS-1) and COX-2 (PGHS-2). The COX-1 and COX-2 isoforms possess 60 percent homology in those amino acid sequences apparently conserved for catalysis of arachidonic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. A splice variant derived from the COX-1 gene has been described as COX-3. The relevance of this isoform is still unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/11\">",
"     11",
"    </a>",
"    ]. There are important differences in the regulation and expression of these enzymes in various tissues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      COX-1 is expressed in most tissues but variably. It is described as a \"housekeeping\" enzyme, regulating normal cellular processes (such as gastric cytoprotection, vascular homeostasis, platelet aggregation, and kidney function), and is stimulated by hormones or growth factors.",
"     </li>",
"     <li>",
"      COX-2 is usually",
"      <strong>",
"       undetectable",
"      </strong>",
"      in most tissues; its expression is increased during states of inflammation, or experimentally in response to mitogenic stimuli. As an example, growth factors, phorbol esters, and interleukin-1 stimulate the expression of COX-2 in fibroblasts, while endotoxin serves the same function in",
"      <span class=\"nowrap\">",
"       monocytes/macrophages",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/5,12\">",
"       5,12",
"      </a>",
"      ]. COX-2 is constitutively expressed in the brain, in the kidney, in bone, and probably in the female reproductive system [",
"      <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/13\">",
"       13",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Another distinguishing characteristic of COX-2 is that its expression is inhibited by glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/14\">",
"       14",
"      </a>",
"      ]. This observation may contribute to the significant antiinflammatory effects of the glucocorticoids.",
"     </li>",
"     <li>",
"      COX-3 appears to be expressed at a high level in the central nervous system with transcripts for this splice-variant accounting for 5 percent of COX mRNA; it is also found in the heart [",
"      <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/11,15\">",
"       11,15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, differences in the effectiveness with which a particular NSAID inhibits an isoform of cyclooxygenase may affect both its activity and toxicity. The efficacy and safety of selective COX-2 inhibitors are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of COX-2 inhibition on inflammation is not completely understood:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      COX-2 knockout mice are as susceptible to inflammation as intact mice [",
"      <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. Paradoxically, COX-1 knockout mice show less ulceration after the administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      than intact mice even though their gastric prostaglandin E2 levels are reduced by 99 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      COX-2 may have antiinflammatory properties. Using an animal model of inflammation and carrageenin-induced pleurisy, one study showed that maximal COX-2 expression coincided with inflammatory resolution and was associated with minimal prostaglandin E2 synthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Human T lymphocytes express the COX-2 isoenzyme where it may serve a role in both the early and late events of T cell activation, such as the production of interleukin-2, tumor necrosis factor alpha, and interferon-gamma [",
"      <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although selective COX-2 inhibition may produce less gastric toxicity, there has been concern that COX-2 inhibition could delay healing of gastric erosions or ulcers and may enhance injury in an inflamed tissue, as in an experimental model of colitis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/21-23\">",
"       21-23",
"      </a>",
"      ]. These observations may have clinical importance in patients with inflammatory bowel disease in whom nonselective NSAIDs can exacerbate the disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A clinically significant delay in healing of ulcers was not observed in the clinical trials of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      . However, approximately 40 percent of the patients included in the trials were required to be free of ulcers prior to study entry. Thus, the effect of celecoxib on ulcer healing in patients with pre-existing ulcer disease has not been well-established.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some older NSAIDs are also relatively selective for the COX-2 receptor at low doses.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/18/39208?source=see_link\">",
"     Nabumetone",
"    </a>",
"    , for example, appears to be a more effective inhibitor in some experimental systems of COX-2 than COX-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/24\">",
"     24",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/35/13881?source=see_link\">",
"     Etodolac",
"    </a>",
"    also inhibits the COX-2 isoform more than COX-1 (10 to 1 ratio) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some clinical data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/18/39208?source=see_link\">",
"     nabumetone",
"    </a>",
"    is also less likely to induce gastric ulcers than other NSAIDs. However, when higher doses of nabumetone are used, relative inhibition of COX-2 decreases, and the risk of ulcer disease increases. In one report, for example, the administration of nabumetone to healthy human volunteers at an adequate antiinflammatory dose inhibited COX-2 and COX-1 to the same degree [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/24\">",
"     24",
"    </a>",
"    ]. Use of an in vitro model showed that 6-MNA (the active metabolite of nabumetone) also equally inhibited both COX isoforms in a whole blood system consisting of inducible mononuclear cells. These results were supported by a second study which found that most NSAIDs did not spare COX-1 activity at therapeutic concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/27\">",
"     27",
"    </a>",
"    ]. The relative gastric protection observed with nabumetone may be due to the neutral state of its prodrug formulation and to the fact that 6-MNA (the active form of the drug) is not a powerful inhibitor of COX at low doses.",
"   </p>",
"   <p>",
"    Further discussion relating to COX-2 inhibitors is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Studies with salicylates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salicylates barely inhibit the cyclooxygenase enzyme in pure cell free enzyme systems, and, in cell membrane systems, their effects are not measurable. However, in a human whole cell system, they are very potent inhibitors of both COX-1 and COX-2, with the latter inducible form being more sensitive to the effects of the drug than the constitutive enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/28\">",
"     28",
"    </a>",
"    ]. Although the nonacetylated salicylates are not good prostaglandin synthesis inhibitors in vitro, clinical studies have shown that these drugs (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5350?source=see_link\">",
"     salsalate",
"    </a>",
"    ) may be as effective as other NSAIDs in patients with RA [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of acetylsalicylic acid (ASA) on COX-2 activity are very different from the effects on COX-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/30\">",
"     30",
"    </a>",
"    ]. Acetylated COX-1 and COX-2 cannot form the intermediate products of prostaglandin synthesis. However, acetylated COX-2 retains the capacity to alter arachidonic acid to form 15R-HETE, while acetylated COX-1 does not. While 15R-HETE has unknown biochemical effects, it may be important as a modulator of proliferation since it is a product of an inducible enzyme during states of inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/30\">",
"     30",
"    </a>",
"    ]. This effect on proliferation may have several interesting ramifications, including the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for the prevention of colon cancer (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Non-prostaglandin mediated effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (the only acetylated NSAID) is not thought to have effects other than those related to inhibition of prostaglandin synthesis, several non-prostaglandin mediated mechanisms of action have been postulated to explain the actions of the nonacetylated salicylates; these observations may also apply, to a varying degree, to the nonsalicylate NSAIDs [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some of these effects appear to be related to the physicochemical property of NSAIDs that enables them to insert into biological membranes and disrupt important interactions necessary for cell function (eg, transmembrane anion transport, oxidative phosphorylation, and uptake of arachidonate).",
"     </li>",
"     <li>",
"      Neutrophil function is inhibited by nonacetylated salicylates and other nonsalicylate NSAIDs in vitro. As an example, NSAIDs interfere with the neutrophil-endothelial cell adherence that is critical for the ability to respond to inflammation. NSAIDs decrease the expression of L-selectin, which removes a crucial step in the migration of granulocytes to sites of inflammation [",
"      <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of these non-prostaglandin mediated processes in clinical inflammation remains unclear. Despite the fact that nonacetylated salicylates have shown equal antiinflammatory efficacy when compared with ASA in patients with rheumatoid arthritis (RA) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/32\">",
"     32",
"    </a>",
"    ], there is no clear evidence that cyclooxygenase inhibition is not achieved at the doses of drug required to achieve an antiinflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/2,3,33\">",
"     2,3,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NSAIDS have also been demonstrated in vitro to inhibit NF-&kappa;B dependent transcription, leading to inhibition of inducible nitric oxide synthetase (iNOS) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/34\">",
"     34",
"    </a>",
"    ]. Nitric oxide synthetase, once induced by cytokines and other proinflammatory mediators, produces NO in large amounts, thereby leading to increased inflammation (including vasocongestion, cytotoxicity, and vascular permeability) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/35\">",
"     35",
"    </a>",
"    ]. Therapeutic levels of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    inhibit expression of iNOS and the subsequent production of nitrite in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/34\">",
"     34",
"    </a>",
"    ]. Sodium salicylate and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    have no such effects at pharmacologic doses, although at suprapharmacologic dosages, sodium salicylate also inhibits nitrite production [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The inhibition of NF-&kappa;B by salicylates may be responsible for the capacity of salicyl salicylate (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5350?source=see_link\">",
"     salsalate",
"    </a>",
"    ) to reduce levels of HbA",
"    <sub>",
"     1c",
"    </sub>",
"    and to improve other markers of glycemic control in patients with type 2 diabetes; such studies were based, in part, on the observation that NF-&kappa;B is activated by obesity and promotes insulin resistance and risk for type 2 diabetes and cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Apoptosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A novel effect of NSAIDs has been described involving prostaglandin inhibition. Prostaglandins inhibit apoptosis (programmed cell death) in vivo; NSAIDs, therefore, establish a more normal cell cycle in the inflammatory state via inhibition of prostaglandin synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/37\">",
"     37",
"    </a>",
"    ]. An important extension of these observations may be the association between the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , and perhaps other NSAIDs, and a reduced risk of colorectal cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22666?source=see_link\">",
"     \"NSAIDs (including aspirin): Role in prevention of cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism of this protective effect cannot be entirely attributed to inhibition of prostaglandin synthesis. The two prerequisites for the development of cancer are proliferation and the inhibition of apoptosis. One study found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/17/44312?source=see_link\">",
"     sulindac",
"    </a>",
"    decreased the size of adenomatous polyps in patients with familial adenomatous polyposis by increasing apoptosis rather than altering proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1336/abstract/38\">",
"     38",
"    </a>",
"    ]. Cell proliferation was studied via immunohistochemistry for cell nuclear antigen in a group of 22 patients randomized to either sulindac (150 mg twice daily) or placebo. Although sulindac caused a significant decrease in polyp size and number after three months, there was no significant change in cytokinetic variables or cell cycle distribution. However, the subdiploid apoptotic fraction was increased significantly in the patients treated with sulindac (31 percent versus 10 percent at baseline).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3847375\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All NSAIDs are absorbed completely, have negligible first-pass hepatic metabolism, are tightly bound to albumin, and have small volumes of distribution. Half-lives of the NSAIDs vary but, in general, can be divided into \"short\" (less than six hours) and \"long\" (more than six hours) acting drugs. Patients with hypoalbuminemia (due, for example, to cirrhosis or active rheumatoid arthritis) may have a higher free serum concentration of the drug. (See",
"      <a class=\"local\" href=\"#H8064364\">",
"       'Pharmacology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Assessment of toxicity and therapeutic response to a given NSAID must take into account the time needed to reach the steady state plasma concentration (roughly equal to three to five half-lives of the drug). Toxicity (eg, gastroduodenal) may vary based upon the extent of enterohepatic circulation, since this defines the length of time a drug comes into direct contact with the gastrointestinal mucosa. The specific choice of one NSAID over another should take into consideration the risk factors for toxic events that individual patients possess and the way in which the drug is metabolized. NSAIDs with a short half-life and no enterohepatic circulation may be the best choices for older debilitated patients. All agents should be used at the lowest effective dose. (See",
"      <a class=\"local\" href=\"#H8064364\">",
"       'Pharmacology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is individual variation in response to NSAIDs; some patients seem to respond better to one drug than to others. The risk of adverse events also varies among individual drugs and patients. These differences have been ascribed to differences in absorption, distribution, and metabolism. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary effect of NSAIDs is to inhibit cyclooxygenase (prostaglandin synthase), thereby impairing the ultimate transformation of arachidonic acid to prostaglandins, prostacyclin, and thromboxanes. The extent of enzyme inhibition varies among the different NSAIDS, although there are no studies relating the degree of cyclooxygenase inhibition with antiinflammatory efficacy in individual patients. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Cyclooxygenase inhibition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two related isoforms of the cyclooxygenase (COX) enzyme have been described: COX-1 (PGHS-1) and COX-2 (PGHS-2). The COX-1 and COX-2 isoforms possess 60 percent homology in those amino acid sequences apparently conserved for catalysis of arachidonic acid. A splice variant derived from the COX-1 gene has been described as COX-3. The relevance of this isoform is still unclear. There are important differences in the regulation and expression of these enzymes in various tissues. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'COX enzymes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      COX-1 is expressed in most tissues but variably. It is described as a \"housekeeping\" enzyme, regulating normal cellular processes (such as gastric cytoprotection, vascular homeostasis, platelet aggregation, and kidney function) and is stimulated by hormones or growth factors. COX-2 is usually undetectable in most tissues; its expression is increased during states of inflammation, or experimentally in response to mitogenic stimuli. COX-2 is constitutively expressed in the brain, in the kidney, in bone, and probably in the female reproductive system; the expression of COX-2 is inhibited by glucocorticoids. Differences in the effectiveness with which a particular NSAID inhibits an isoform of cyclooxygenase may affect both its activity and toxicity. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'COX enzymes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Salicylates barely inhibit the cyclooxygenase enzyme in pure cell free enzyme systems, and, in cell membrane systems, their effects are not measurable. However, in a human whole cell system, they are very potent inhibitors of both COX-1 and COX-2, with the latter inducible form being more sensitive to the effects of the drug than the constitutive enzyme. Although the nonacetylated salicylates are not good prostaglandin synthesis inhibitors in vitro, clinical studies have shown that these drugs (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5350?source=see_link\">",
"       salsalate",
"      </a>",
"      ) may be as effective as other NSAIDs in patients with RA. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Studies with salicylates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several non-prostaglandin mediated mechanisms of action have been postulated to explain the actions of the nonacetylated salicylates; these observations may also apply, to a varying degree, to the nonsalicylate NSAIDs. These include disruption of interactions necessary for cell function through actions in cell membranes and inhibition of neutrophil function, including endothelial cell adherence, by nonacetylated salicylates and other nonsalicylate NSAIDs in vitro. NSAIDS have also been demonstrated in vitro to inhibit NF-&kappa;B dependent transcription, leading to inhibition of inducible nitric oxide synthetase (iNOS). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Non-prostaglandin mediated effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/1\">",
"      Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/2\">",
"      Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs--differences and similarities. N Engl J Med 1991; 324:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/3\">",
"      Abramson SB, Weissmann G. The mechanisms of action of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1989; 32:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/4\">",
"      Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993; 268:6610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/5\">",
"      DeWitt DL, Meade EA, Smith WL. PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs. Am J Med 1993; 95:40S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/6\">",
"      DeWitt DL, el-Harith EA, Kraemer SA, et al. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J Biol Chem 1990; 265:5192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/7\">",
"      Shimokawa T, Smith WL. Prostaglandin endoperoxide synthase. The aspirin acetylation region. J Biol Chem 1992; 267:12387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/8\">",
"      Shimokawa T, Smith WL. Essential histidines of prostaglandin endoperoxide synthase. His-309 is involved in heme binding. J Biol Chem 1991; 266:6168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/9\">",
"      Shimokawa T, Kulmacz RJ, DeWitt DL, Smith WL. Tyrosine 385 of prostaglandin endoperoxide synthase is required for cyclooxygenase catalysis. J Biol Chem 1990; 265:20073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/10\">",
"      Toh H. Prostaglandin endoperoxide synthase contains an EGF-like domain. FEBS Lett 1989; 258:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/11\">",
"      Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002; 99:13926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/12\">",
"      Lee SH, Soyoola E, Chanmugam P, et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992; 267:25934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/13\">",
"      Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998; 12:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/14\">",
"      O'Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci U S A 1992; 89:4888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/15\">",
"      Schwab JM, Schluesener HJ, Laufer S. COX-3: just another COX or the solitary elusive target of paracetamol? Lancet 2003; 361:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/16\">",
"      Morham SG, Langenbach R, Loftin CD, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995; 83:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/17\">",
"      Dinchuk JE, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995; 378:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/18\">",
"      Langenbach R, Morham SG, Tiano HF, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995; 83:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/19\">",
"      Gilroy DW, Colville-Nash PR, Willis D, et al. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999; 5:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/20\">",
"      I&ntilde;iguez MA, Punz&oacute;n C, Fresno M. Induction of cyclooxygenase-2 on activated T lymphocytes: regulation of T cell activation by cyclooxygenase-2 inhibitors. J Immunol 1999; 163:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/21\">",
"      Mizuno H, Sakamoto C, Matsuda K, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997; 112:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/22\">",
"      Reuter BK, Asfaha S, Buret A, et al. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 1996; 98:2076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/23\">",
"      Newberry RD, Stenson WF, Lorenz RG. Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen. Nat Med 1999; 5:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/24\">",
"      Roth SH. NSAID gastropathy. A new understanding. Arch Intern Med 1996; 156:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/25\">",
"      Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994; 271:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/26\">",
"      Glaser K, Sung ML, O'Neill K, et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol 1995; 281:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/27\">",
"      Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/28\">",
"      Mitchell JA, Akarasereenont P, Thiemermann C, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A 1993; 90:11693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/29\">",
"      Bombardier C, Peloso PM, Goldsmith CH. Salsalate, a nonacetylated salicylate, is as efficacious as diclofenac in patients with rheumatoid arthritis. Salsalate-Diclofenac Study Group. J Rheumatol 1995; 22:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/30\">",
"      Marcus AJ. Aspirin as prophylaxis against colorectal cancer. N Engl J Med 1995; 333:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/31\">",
"      D&iacute;az-Gonz&aacute;lez F, Gonz&aacute;lez-Alvaro I, Campanero MR, et al. Prevention of in vitro neutrophil-endothelial attachment through shedding of L-selectin by nonsteroidal antiinflammatory drugs. J Clin Invest 1995; 95:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/32\">",
"      Does the acetyl group of aspirin contribute to the antiinflammatory efficacy of salicylic acid in the treatment of rheumatoid arthritis? The Multicenter Salsalate/Aspirin Comparison Study Group. J Rheumatol 1989; 16:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/33\">",
"      Stevenson DD, Hougham AJ, Schrank PJ, et al. Salsalate cross-sensitivity in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 1990; 86:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/34\">",
"      Amin AR, Vyas P, Attur M, et al. The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase. Proc Natl Acad Sci U S A 1995; 92:7926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/35\">",
"      Hawkey CJ. Future treatments for arthritis: new NSAIDs, NO NSAIDs, or no NSAIDs? Gastroenterology 1995; 109:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/36\">",
"      Goldfine AB, Fonseca V, Jablonski KA, et al. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 2010; 152:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/37\">",
"      Lu X, Xie W, Reed D, et al. Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts. Proc Natl Acad Sci U S A 1995; 92:7961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1336/abstract/38\">",
"      Pasricha PJ, Bedi A, O'Connor K, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995; 109:994.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7989 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-AE2128909E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_19_1336=[""].join("\n");
var outline_f1_19_1336=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3847375\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8064364\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8064259\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8064004\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8064062\">",
"      - Angiotensin converting enzyme inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8064055\">",
"      - Low-dose aspirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8064223\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8064272\">",
"      - SSRIs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8064180\">",
"      - Warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cyclooxygenase inhibition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - COX enzymes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Studies with salicylates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Non-prostaglandin mediated effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Apoptosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3847375\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7989\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7989|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/29/34269\" title=\"figure 1\">",
"      Prostaglandin synthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7989|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/54/24431\" title=\"table 1\">",
"      Nonopioid analgesic and NSAID table",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=related_link\">",
"      Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=related_link\">",
"      NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22666?source=related_link\">",
"      NSAIDs (including aspirin): Role in prevention of cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=related_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_19_1337="Clinical presentation and diagnosis of IgA nephropathy";
var content_f1_19_1337=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical presentation and diagnosis of IgA nephropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/19/1337/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/19/1337/contributors\">",
"     Jonathan Barratt, PhD, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/19/1337/contributors\">",
"     John Feehally, DM, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/19/1337/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/19/1337/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/19/1337/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/19/1337/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/19/1337/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgA nephropathy is the most common lesion found to cause primary glomerulonephritis throughout most developed countries of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. Patients may present at any age, but there is a peak incidence in the second and third decades of life. There is approximately a 2:1 male to female predominance in North American and Western European populations, although this difference is not observed among populations in the Pacific Rim.",
"   </p>",
"   <p>",
"    IgA nephropathy occurs with greatest frequency in Asians and Caucasians, and is relatively rare in blacks [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/3,5,8\">",
"     3,5,8",
"    </a>",
"    ]. In a Chinese study of 13,519 renal biopsies, for example, IgA nephropathy constituted 45 percent of all cases of primary glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/5\">",
"     5",
"    </a>",
"    ]. However, IgA deposits may also be seen on kidney biopsy in individuals with no evidence of renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reported incidence of mesangial IgA deposition in apparently healthy individuals ranges from 3 to 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. These cases had no clinical features of nephritis but their renal biopsy was consistent with IgA nephropathy.",
"   </p>",
"   <p>",
"    This observation raises three important points:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a large cohort of undiagnosed \"latent\" IgA nephropathy in the general population.",
"     </li>",
"     <li>",
"      This must be taken into account when genetic studies are undertaken comparing gene polymorphisms in IgA nephropathy with normal \"healthy\" populations.",
"     </li>",
"     <li>",
"      It raises an important consideration for the pathogenesis of IgA nephropathy: the process of mesangial IgA deposition is likely to be separate from the induction of glomerular injury and IgA deposition does not necessarily need to be followed by nephritis. Identifying the factors common to both processes is essential to our overall understanding of the pathogenesis of IgA nephropathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are also a number of reports documenting IgA deposition in other forms of glomerulonephritis. These particularly include thin basement membrane nephropathy, lupus nephritis, minimal change disease, and diabetic nephropathy. These findings are most probably due to chance associations, since IgA deposition is common in the general population.",
"   </p>",
"   <p>",
"    Variations in disease prevalence may in large part reflect regional differences in screening for kidney disease and kidney biopsy practices [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Many patients with IgA nephropathy are detected on routine urine screening, since their only clinical manifestation is asymptomatic hematuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proteinuria. Prevalence may therefore appear to be higher in countries with an active urine testing program and a low threshold for the performance of renal biopsy in patients with isolated asymptomatic hematuria, such as Japan, where testing is routinely performed in schools and in the workplace. Conversely, clinicians in North America seldom biopsy a patient with isolated hematuria or mild proteinuria, resulting in an apparently lower disease prevalence.",
"   </p>",
"   <p>",
"    The pathology, clinical features, and diagnosis of IgA nephropathy will be reviewed here. The pathogenesis, treatment and prognosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/48/20233?source=see_link\">",
"     \"Pathogenesis of IgA nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42106?source=see_link\">",
"     \"Treatment and prognosis of IgA nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of IgA nephropathy is established only by kidney biopsy. The pathognomonic finding is observed on immunofluorescence microscopy, which demonstrates prominent, globular deposits of IgA (often accompanied by C3 and IgG) in the mesangium and, to a lesser degree, along the glomerular capillary wall (",
"    <a class=\"graphic graphic_picture graphicRef62380 \" href=\"UTD.htm?28/4/28745\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef69895 \" href=\"UTD.htm?23/2/23599\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef58102 \" href=\"UTD.htm?12/0/12297\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This deposited IgA is predominantly J chain containing polymeric IgA1. Mesangial deposition of secretory IgA has also been observed, although the pathogenic significance of this is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The immunofluorescence findings in IgA nephropathy are indistinguishable from those in Henoch-Sch&ouml;nlein purpura (IgA vasculitis). (See",
"    <a class=\"medical medical_review\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis?source=see_link\">",
"     \"Renal manifestations of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major finding on light microscopy is focal (involving less than 50 percent of glomeruli) or more often diffuse mesangial proliferation and matrix expansion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/2\">",
"     2",
"    </a>",
"    ]. Segmental crescents are relatively common, although they may be missed by sampling error if only a few glomeruli are obtained. In patients with IgA nephropathy and rapidly deteriorating renal function, segmental necrosis with or without crescent formation is often seen, a finding consistent with an ongoing \"capillaritis.\"",
"   </p>",
"   <p>",
"    There is usually little or no glomerulosclerosis, a manifestation of chronic disease, on initial biopsy. Patients may eventually develop glomerulosclerosis, by which time they have decreased glomerular filtration rate (GFR) and increased proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electron microscopy typically reveals electron-dense deposits that are primarily limited to the mesangium (which are outside of mesangial cells in the mesangial spaces) but may also occur in the subendothelial and subepithelial spaces. The number and size of these deposits generally correlates well with the severity of changes seen on light microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients with IgA nephropathy have co-existing diffuse thinning of the glomerular basement membrane that is indistinguishable from thin basement membrane nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. It is not clear whether the clinical course of such patients differs from typical IgA nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12088?source=see_link\">",
"     \"Thin basement membrane nephropathy (benign familial hematuria)\"",
"    </a>",
"    .) Preliminary work from France suggests that such patients may have a more benign outcome, due possibly to lead-time bias, as hematuria brings them to the attention of clinicians at an earlier time in the natural history of disease.",
"   </p>",
"   <p>",
"    Lupus nephritis is another disorder associated with prominent mesangial IgA deposition. Lupus can be distinguished from IgA nephropathy histologically by the more prominent deposition of IgG than IgA and the presence of substantial C1q deposition, indicating activation of the classic complement pathway, as opposed to the alternate pathway activation in IgA nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27706?source=see_link\">",
"     \"Diagnosis and classification of renal disease in systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Oxford classification of IgA nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A consensus on the pathologic classification of IgA nephropathy has been developed by the International IgA nephropathy Network in collaboration with the Renal Pathology Society [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In order to develop this classification, clinical data and renal biopsies were obtained from 265 patients who were followed for a median of five years. Repeated analysis by several pathologists identified histologic variables that were consistently interpreted with a high degree of reproducibility. In a retrospective analysis, the following variables correlated with renal outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mesangial hypercellularity",
"     </li>",
"     <li>",
"      Segmental glomerulosclerosis",
"     </li>",
"     <li>",
"      Endocapillary hypercellularity",
"     </li>",
"     <li>",
"      Tubular",
"      <span class=\"nowrap\">",
"       atrophy/interstitial",
"      </span>",
"      fibrosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The predictive value of each of these variables appears to be similar in adults and children [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on these data, the consensus recommendation is that every biopsy report of IgA nephropathy include numerical scores based on the presence or absence of these variables. The suggested scoring system is defined below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mesangial hypercellularity &mdash; Mesangial cells are counted per mesangial area and a score of 0-3 is assigned for each glomerulus. a score of zero indicates that fewer than 4 mesangial cells are present per mesangial area; a score of one indicates that 4-5 mesangial cells are present per mesangial area; a score of two indicates that 6-7 mesangial cells are present per mesangial area; a score of three indicates that greater than 8 mesangial cells are present per mesangial area. Scores obtained for all glomeruli are averaged and the resulting assigned hypercellularity score is either M0 if the mean score is less than 0.5 or M1 if the mean score is greater than 0.5.",
"     </li>",
"     <li>",
"      Segmental glomerulosclerosis &mdash; Defined as present (S1) if any part of the glomerular tuft is involved in sclerosis, or absent (S0) if no segmental glomerulosclerosis is present.",
"     </li>",
"     <li>",
"      Endocapillary hypercellularity &mdash; Defined as present (E1) if hypercellularity is present within the glomerular capillary lumina and results in narrowing of the lumina, or absent (E0) if no hypercellularity is present within lumina.",
"     </li>",
"     <li>",
"      Tubular",
"      <span class=\"nowrap\">",
"       atrophy/interstitial",
"      </span>",
"      fibrosis &mdash; The percentage of the cortical area involved by tubular atrophy or interstitial fibrosis is quantitated. A score of T0, T1 or T2 is given if the percentage of involved cortical area is 0-25; 26-50 or &gt;50 percent, respectively.",
"     </li>",
"     <li>",
"      Biopsies with fewer than eight glomeruli should be considered of uncertain value for prognosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A potential weakness of this classification system is that it does not include crescents or necrotizing lesions, as too few of these lesions were found in the data set due to inclusion and exclusion criteria. The prognostic utility of this scoring system needs to be validated using further patient cohorts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with IgA nephropathy typically present in one of three ways; the relative frequency depends in part upon screening practices (which will lead to increased discovery of asymptomatic cases) and the particular population being evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 40 to 50 percent present with one or recurrent episodes of visible hematuria, usually following an upper respiratory infection. This has sometimes been called 'synpharyngitic hematuria'. These episodes can be provoked by bacterial tonsillitis, or by other viral upper respiratory infections; they may occur in individuals who have already undergone tonsillectomy. It is presumed, although not proven, that the first episode represents the onset of the disease. Patients may complain of flank pain during acute episodes, which usually reflects stretching of the renal capsules. Low grade fever may also be present. These features can mimic urinary tract infection or urolithiasis. Most patients have only a few episodes of visible hematuria and episodes usually recur for a few years at most. A discussion of clinical clues that may distinguish IgA nephropathy from poststreptococcal glomerulonephritis can be found separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link&amp;anchor=H14578038#H14578038\">",
"       \"Differential diagnosis and evaluation of glomerular disease\", section on 'Hematuria following upper respiratory infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Another 30 to 40 percent have microscopic hematuria and usually mild proteinuria, and are incidentally detected on a routine examination [",
"      <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. In these patients, the disease is of uncertain duration. Gross hematuria will eventually occur in 20 to 25 percent of these patients",
"     </li>",
"     <li>",
"      Less than 10 percent present with either nephrotic syndrome or acute rapidly progressive glomerulonephritis picture characterized by edema, hypertension, and renal insufficiency as well as hematuria. Rarely, IgA nephropathy may present with malignant hypertension. It is usually presumed that patients have longstanding disease which was not detected earlier because the patient did not have visible hematuria or undergo routine urinalysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Issues related to treatment and prognosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42106?source=see_link\">",
"     \"Treatment and prognosis of IgA nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, patients develop acute kidney injury with or without oliguria. This may be due to crescentic IgA nephropathy, or to heavy glomerular hematuria leading to tubular occlusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    damage by red cells. The latter is usually a reversible phenomenon, although incomplete recovery of renal function may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If there is crescentic IgA nephropathy, there will be an increase in the absolute number of dysmorphic red cells excreted in the urine which is typically at least 50 percent of all red cells seen, and always an absolute increase in the number of dysmorphic cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42106?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment and prognosis of IgA nephropathy\", section on 'Acute renal failure with gross hematuria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among affected families, the disease appears to be transmitted as an autosomal dominant trait with incomplete penetrance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of IgA nephropathy are clinically restricted to the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/1-3,7\">",
"     1-3,7",
"    </a>",
"    ], but it may be associated with other conditions. Some associations are well established, others are anecdotal observations that should be interpreted with caution since IgA nephropathy is a common disease, and any association may be coincidental rather than causal.",
"   </p>",
"   <p>",
"    Cirrhosis, celiac disease, and HIV infection are all associated with a high frequency of glomerular IgA deposition. However, most patients have little or no evidence of glomerular disease. These observations indicate that a high circulating load of polyclonal IgA is not of itself adequate to promote the nephritis characteristic of IgA nephropathy and that other abnormalities of IgA and its metabolism, as discussed previously, are necessary for IgA deposition to translate into mesangial activation and glomerular injury. It is also important to note that the reported incidence of mesangial IgA deposition in apparently healthy individuals ranges from 3 to 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Therefore, the likelihood of finding mesangial IgA deposits by chance in association with other common diseases is relatively high.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cirrhosis and other forms of severe liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesangial IgA deposition associated with chronic liver disease, particularly alcoholic cirrhosis, is the most common form of secondary IgA nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. It can also occur in chronic liver disease due to other causes, including hepatitis B and C [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/23,24\">",
"     23,24",
"    </a>",
"    ] and, in children, end-stage liver disease due mostly to alpha 1-antitrypsin deficiency or biliary atresia. In a study of 18 children in whom renal biopsy was performed at the time of hepatic transplantation, evidence of glomerulonephritis was seen in all [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/25\">",
"     25",
"    </a>",
"    ]. Most patients had IgA nephropathy, but several had a membranoproliferative picture without apparent immune complex deposition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18136?source=see_link\">",
"     \"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Impaired removal of IgA-containing complexes by the Kupffer cells in the liver is thought to predispose to IgA deposition in the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/26\">",
"     26",
"    </a>",
"    ]. The observation that IgA may also be deposited in the skin and hepatic sinusoids is compatible with this hypothesis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/27\">",
"     27",
"    </a>",
"    ]. Studies of IgA subclass distribution in IgA deposits in liver disease have been contradictory. As in primary IgA nephropathy, polymeric IgA1 appears to be the dominant IgA isoform deposited, although there is some evidence for co-deposition of IgA2.",
"   </p>",
"   <p>",
"    Despite the frequency of glomerular IgA deposits in advanced liver disease, most adults have no clinical signs of glomerular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/21-23\">",
"     21-23",
"    </a>",
"    ], while up to one-third of children may have asymptomatic hematuria or proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/25\">",
"     25",
"    </a>",
"    ]. The urinary abnormalities that may be seen in children typically resolve after successful hepatic transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The general dissociation between the histologic and clinical manifestations may be related to the lack of concurrent IgG deposition, thereby minimizing complement activation and local inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/2,28\">",
"     2,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/48/20233?source=see_link&amp;anchor=H9#H9\">",
"     \"Pathogenesis of IgA nephropathy\", section on 'Development of glomerular injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glomerular IgA deposition is common in celiac disease (gluten enteropathy), occurring in as many as one-third of patients. As in cirrhosis, the great majority of affected patients have no clinical manifestations of renal disease, perhaps because there is no associated activation of complement [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ingestion of gliadin in this disorder leads to the formation of IgA antigliadin antibodies, with the subsequent deposition of gliadin-antigliadin immune complexes in the glomeruli [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/30\">",
"     30",
"    </a>",
"    ]. This can occur in patients both with overt gluten enteropathy and those with no symptoms but mucosal atrophy on intestinal biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The level of circulating IgA complexes appears to correlate with disease activity in the occasional patient with clinically evident IgA nephropathy. However, gliadin deposition cannot be demonstrated in the glomeruli, suggesting that gluten might act by increasing intestinal permeability and enhancing the absorption of other dietary antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It remains unclear how often gliadin is an important pathogenetic factor in IgA nephropathy. It has been suggested that up to 35 percent of IgA nephropathy patients in Italy may have IgA antigliadin antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/31\">",
"     31",
"    </a>",
"    ]. Institution of a gluten-free diet in patients with circulating antigliadin antibodies results, in most cases, in a temporary but non-sustained reduction in hematuria and proteinuria and has no impact on long-term renal survival [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the collapsing variant of focal segmental glomerulosclerosis is the classic glomerulopathy seen with HIV infection, a range of other glomerular diseases are seen in association with HIV infection, and IgA nephropathy is increasingly reported [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Patients with IgA nephropathy present with visible or invisible hematuria and asymptomatic proteinuria compared with the nephrotic syndrome in focal segmental glomerulosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electron microscopy typically reveals multiple tubuloreticular structures in the endothelial cells; this finding suggests underlying HIV infection, rather than some other form of IgA nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4168?source=see_link\">",
"     \"Overview of kidney disease in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The polyclonal increase in serum IgA, which is a feature of AIDS, has been cited as a predisposing factor. In at least some cases of HIV-associated IgA nephropathy, idiotypic IgA antibodies reactive with anti-HIV IgG or IgM antibodies can be demonstrated both in the systemic circulation and in the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/35\">",
"     35",
"    </a>",
"    ]. Furthermore, the HIV genome can be detected in the kidney, suggesting a possible initiating role of viral infection in the glomerular cells.",
"   </p>",
"   <p>",
"    The prevalence of IgA deposits in patients infected with HIV is uncertain. One report of 116 postmortem examinations found mesangial IgA deposits in 8 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/33\">",
"     33",
"    </a>",
"    ]. However, most affected patients had little or no mesangial hypercellularity and urinary abnormalities were mild in all cases. Thus, subclinical disease or incidental IgA deposition appears to be much more common than overt IgA nephropathy, similar to the findings noted above in cirrhosis and celiac disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Minimal change disease and membranous nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nephrotic syndrome in IgA nephropathy is usually indicative of advanced disease. However, some patients have an acute onset of the nephrotic syndrome in which there is only mild mesangial proliferation on renal biopsy and the most prominent finding is diffuse fusion of the foot processes, similar to that seen in minimal change disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. Furthermore, many of these patients behave as if they have minimal change disease, with remission of proteinuria being induced by glucocorticoid therapy. The mechanism underlying this association is not understood, and the IgA deposits may represent a chance occurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42106?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment and prognosis of IgA nephropathy\", section on 'Glucocorticoids as sole immunosuppressive/antiinflammatory therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IgA nephropathy has also been reported to overlap with membranous nephropathy in a smaller number of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In this setting, patients present with both hematuria (with mesangial IgA deposits and mesangial cell proliferation characteristic of IgA nephropathy) and proteinuria (with prominent IgG subepithelial deposits characteristic of membranous nephropathy). Whether these disorders are related or have occurred concurrently is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Granulomatosis with polyangiitis (Wegener's)",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgA nephropathy has been described in patients with granulomatosis with polyangiitis (Wegener's) who were in clinical remission after initial immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/43\">",
"     43",
"    </a>",
"    ]. These patients had repeated upper respiratory infections (perhaps due in part to the immunosuppression) and presented with new hematuria, but no apparent recurrence of systemic vasculitis or new elevation in ANCA titers. The latter findings suggest the possibility of a new renal disease rather than relapsing vasculitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9130?source=see_link\">",
"     \"Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Optimal therapy in this setting is uncertain. In at least some patients, the degree of hematuria is reduced following cessation of immunosuppressive therapy, suggesting that the recurrent infections may have been etiologically important [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgA nephropathy has been infrequently associated with a variety of other diseases including dermatitis herpetiformis, seronegative arthritis (particularly ankylosing spondylitis), small cell carcinoma, lymphoma (Hodgkin lymphoma and T-cell lymphomas, including mycosis fungoides), disseminated tuberculosis, bronchiolitis obliterans, and inflammatory bowel disease (Crohn's disease and ulcerative colitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/1,44-51\">",
"     1,44-51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The suspicion of a diagnosis of IgA nephropathy is generally based upon the clinical history and laboratory data. The diagnosis can be confirmed",
"    <strong>",
"     only",
"    </strong>",
"    by kidney biopsy with immunofluorescence or immunoperoxidase studies for IgA deposits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103350371\">",
"    <span class=\"h2\">",
"     Indications for renal biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the generally benign course of patients with IgA nephropathy who have isolated hematuria, a renal biopsy is usually performed only if there are signs suggestive of more severe or progressive disease such as persistent protein excretion above 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (which may increase over time) or an elevated serum creatinine concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/52\">",
"     52",
"    </a>",
"    ]. New onset hypertension or a significant elevation in blood pressure above a previous stable baseline that does not exceed",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg (eg, from",
"    <span class=\"nowrap\">",
"     100/60",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg) is also associated with a greater likelihood of progressive disease but is primarily seen in patients who also have one or both of the other adverse predictors.",
"   </p>",
"   <p>",
"    The supportive data and other possible indications for renal biopsy in patients with glomerular hematuria are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42106?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment and prognosis of IgA nephropathy\", section on 'Clinical predictors of progression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link&amp;anchor=H11678456#H11678456\">",
"     \"Etiology and evaluation of hematuria in adults\", section on 'Role of renal biopsy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21690?source=see_link&amp;anchor=H3#H3\">",
"     \"Indications for and complications of renal biopsy\", section on 'Indications and when biopsy may not be necessary'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103350402\">",
"    <span class=\"h2\">",
"     Tests of limited utility",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other tests have been proposed for the evaluation of possible IgA nephropathy but none is recommended:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although circulating autoantibodies, including anti-endothelin antibodies have been reported in IgA nephropathy, none appear to be disease-specific:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Circulating IgA-rheumatoid factors and IgA-immune complexes have been considered as diagnostic markers but are not diagnostically useful, nor can they be reliably correlated with disease activity.",
"     </li>",
"     <li>",
"      Circulating IgA-fibronectin complexes were proposed as a diagnostic test, since their presence carried the implication that increased reactivity between patient IgA and fibronectin within the glomerular mesangium might provide an explanation for mesangial IgA deposition. However, it is now clear that the assays developed for this purpose do not reliably distinguish between IgA complexed to fibronectin and free IgA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin biopsy, looking for IgA deposition in the dermal capillaries, has not proven to be sufficiently predictive in IgA nephropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Plasma polymeric IgA1 levels are elevated in 30 to 50 percent of cases, but this suggestive finding is not sufficiently specific to establish the diagnosis.",
"     </li>",
"     <li>",
"      Measurement of the proportion of poorly galactosylated IgA1 O-glycoforms in the serum with or without measurement of poorly galactosylated IgA1-specific IgG antibodies has been proposed as a clinically useful diagnostic test [",
"      <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/54-56\">",
"       54-56",
"      </a>",
"      ]. However, the utility of both assays is unclear since neither has been evaluated in patients who do not have IgA nephropathy but who present similarly to those with IgA nephropathy, such as those with hematuria or renal failure [",
"      <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Differential diagnosis",
"    </strong>",
"    &mdash; Hereditary nephritis and thin basement membrane nephropathy are the two other major glomerulopathies that present with persistent isolated hematuria [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1337/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. The diagnosis of any of these disorders can only be made by renal biopsy, or by inference in hereditary nephritis if there is a family history of renal failure with or without deafness, or in thin basement membrane disease if approximately one-half of first-degree relatives have hematuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/2/17445?source=see_link\">",
"     \"Glomerular hematuria: IgA; Alport; thin basement membrane nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Membranoproliferative GN may also present with episodic visible hematuria in children and young adults, and should therefore be considered in the differential diagnosis.",
"   </p>",
"   <p>",
"    The renal disease in Henoch-Sch&ouml;nlein purpura (IgA vasculitis) is histologically identical to that in IgA nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis?source=see_link\">",
"     \"Renal manifestations of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/62/12257?source=see_link\">",
"       \"Patient information: IgA nephropathy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IgA nephropathy is the most common cause of primary glomerulonephritis. IgA nephropathy is more common among Asians and Caucasians. There is a 2:1 male to female predominance in Caucasians but not Asians. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IgA nephropathy is characterized pathologically by prominent, globular deposits of IgA in the mesangium on immunofluorescence microscopy. Light microscopy shows diffuse mesangial proliferation and matrix expansion with proliferative glomerulonephritis and crescents in more advanced disease. Electron microscopy shows dense deposits primarily in the mesangium (",
"      <a class=\"graphic graphic_picture graphicRef62380 \" href=\"UTD.htm?28/4/28745\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef69895 \" href=\"UTD.htm?23/2/23599\">",
"       picture 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef58102 \" href=\"UTD.htm?12/0/12297\">",
"       picture 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Manifestations of IgA nephropathy are restricted to the kidney. Mesangial IgA deposition, which is often clinically silent, may also be seen with cirrhosis, celiac disease and HIV infection (in which clinically apparent disease may also occur). In addition, IgA nephropathy may rarely be seen with other glomerular diseases, including minimal change disease and granulomatosis with polyangiitis (Wegener's). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical associations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with IgA nephropathy present with either visible hematuria (single or recurrent), usually following an upper respiratory infection, or invisible hematuria with or without mild proteinuria incidentally detected on a routine examination. Rarely, patients may develop acute kidney injury with or without oliguria, due either to crescentic IgA nephropathy, or to gross hematuria causing tubular occlusion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      damage by red cells. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of IgA nephropathy is often suspected on the basis of the clinical history, but can be confirmed only by kidney biopsy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A kidney biopsy is usually performed for the evaluation of suspected IgA nephropathy only if there are signs suggestive of more severe or progressive disease such as protein excretion above 0.5 to 1",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      elevated serum creatinine concentration, or hypertension. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Oxford classification identifies variables that are correlated with renal outcomes independent of the clinical features at baseline, the proteinuria level and blood-pressure control. The prognostic utility of this scoring system needs to be validated before it is used in determining treatment. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Oxford classification of IgA nephropathy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/1\">",
"      D'Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 2004; 24:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/2\">",
"      Emancipator SN. IgA nephropathy: morphologic expression and pathogenesis. Am J Kidney Dis 1994; 23:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/3\">",
"      Galla JH. IgA nephropathy. Kidney Int 1995; 47:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/4\">",
"      Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002; 347:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/5\">",
"      Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int 2004; 66:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/6\">",
"      Simon P, Ramee MP, Boulahrouz R, et al. Epidemiologic data of primary glomerular diseases in western France. Kidney Int 2004; 66:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/7\">",
"      Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol 2005; 16:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/8\">",
"      Crowley-Nowick PA, Julian BA, Wyatt RJ, et al. IgA nephropathy in blacks: studies of IgA2 allotypes and clinical course. Kidney Int 1991; 39:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/9\">",
"      Suzuki K, Honda K, Tanabe K, et al. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 2003; 63:2286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/10\">",
"      Waldherr R, Rambausek M, Duncker WD, Ritz E. Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol Dial Transplant 1989; 4:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/11\">",
"      Oortwijn BD, Rastaldi MP, Roos A, et al. Demonstration of secretory IgA in kidneys of patients with IgA nephropathy. Nephrol Dial Transplant 2007; 22:3191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/12\">",
"      Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis 1997; 29:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/13\">",
"      Dysart NK Jr, Sisson S, Vernier RL. Immunoelectron microscopy of IgA nephropathy. Clin Immunol Immunopathol 1983; 29:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/14\">",
"      Lee HS, Choi Y, Lee JS, et al. Ultrastructural changes in IgA nephropathy in relation to histologic and clinical data. Kidney Int 1989; 35:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/15\">",
"      Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/16\">",
"      Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts IS, Cook HT, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009; 76:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/17\">",
"      Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Coppo R, Troyanov S, et al. The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int 2010; 77:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/18\">",
"      Hall CL, Bradley R, Kerr A, et al. Clinical value of renal biopsy in patients with asymptomatic microscopic hematuria with and without low-grade proteinuria. Clin Nephrol 2004; 62:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/19\">",
"      Topham PS, Harper SJ, Furness PN, et al. Glomerular disease as a cause of isolated microscopic haematuria. Q J Med 1994; 87:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/20\">",
"      Guti&eacute;rrez E, Gonz&aacute;lez E, Hern&aacute;ndez E, et al. Factors that determine an incomplete recovery of renal function in macrohematuria-induced acute renal failure of IgA nephropathy. Clin J Am Soc Nephrol 2007; 2:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/21\">",
"      Newell GC. Cirrhotic glomerulonephritis: incidence, morphology, clinical features, and pathogenesis. Am J Kidney Dis 1987; 9:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/22\">",
"      Pouria S, Feehally J. Glomerular IgA deposition in liver disease. Nephrol Dial Transplant 1999; 14:2279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/23\">",
"      McGuire BM, Julian BA, Bynon JS Jr, et al. Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med 2006; 144:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/24\">",
"      Wang NS, Wu ZL, Zhang YE, et al. Role of hepatitis B virus infection in pathogenesis of IgA nephropathy. World J Gastroenterol 2003; 9:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/25\">",
"      Noble-Jamieson G, Thiru S, Johnston P, et al. Glomerulonephritis with end-stage liver disease in childhood. Lancet 1992; 339:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/26\">",
"      Amore A, Coppo R, Roccatello D, et al. Experimental IgA nephropathy secondary to hepatocellular injury induced by dietary deficiencies and heavy alcohol intake. Lab Invest 1994; 70:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/27\">",
"      van de Wiel A, Valentijn RM, Schuurman HJ, et al. Circulating IgA immune complexes and skin IgA deposits in liver disease. Relation to liver histopathology. Dig Dis Sci 1988; 33:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/28\">",
"      Rauterberg EW, Lieberknecht HM, Wingen AM, Ritz E. Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis. Kidney Int 1987; 31:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/29\">",
"      Pasternack A, Collin P, Mustonen J, et al. Glomerular IgA deposits in patients with celiac disease. Clin Nephrol 1990; 34:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/30\">",
"      Fornasieri A, Sinico RA, Maldifassi P, et al. IgA-antigliadin antibodies in IgA mesangial nephropathy (Berger's disease). Br Med J (Clin Res Ed) 1987; 295:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/31\">",
"      Coppo R, Amore A, Roccatello D. Dietary antigens and primary immunoglobulin A nephropathy. J Am Soc Nephrol 1992; 2:S173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/32\">",
"      Russell MW, Mestecky J, Julian BA, Galla JH. IgA-associated renal diseases: antibodies to environmental antigens in sera and deposition of immunoglobulins and antigens in glomeruli. J Clin Immunol 1986; 6:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/33\">",
"      Beaufils H, Jouanneau C, Katlama C, et al. HIV-associated IgA nephropathy--a post-mortem study. Nephrol Dial Transplant 1995; 10:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/34\">",
"      Katz A, Bargman JM, Miller DC, et al. IgA nephritis in HIV-positive patients: a new HIV-associated nephropathy? Clin Nephrol 1992; 38:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/35\">",
"      Kimmel PL, Phillips TM, Ferreira-Centeno A, et al. Brief report: idiotypic IgA nephropathy in patients with human immunodeficiency virus infection. N Engl J Med 1992; 327:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/36\">",
"      Weiner NJ, Goodman JW, Kimmel PL. The HIV-associated renal diseases: current insight into pathogenesis and treatment. Kidney Int 2003; 63:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/37\">",
"      Mustonen J, Pasternack A, Rantala I. The nephrotic syndrome in IgA glomerulonephritis: response to corticosteroid therapy. Clin Nephrol 1983; 20:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/38\">",
"      Cheng IK, Chan KW, Chan MK. Mesangial IgA nephropathy with steroid-responsive nephrotic syndrome: disappearance of mesangial IgA deposits following steroid-induced remission. Am J Kidney Dis 1989; 14:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/39\">",
"      Westhoff TH, Waldherr R, Loddenkemper C, et al. Mesangial IgA deposition in minimal change nephrotic syndrome: coincidence of different entities or variant of minimal change disease? Clin Nephrol 2006; 65:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/40\">",
"      Barbiano di Belgiojoso G, Mazzucco G, Casanova S, et al. Steroid-sensitive nephrotic syndrome with mesangial IgA deposits: a separate entity? Observation of two cases. Am J Nephrol 1986; 6:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/41\">",
"      Jennette JC, Newman WJ, Diaz-Buxo JA. Overlapping IgA and membranous nephropathy. Am J Clin Pathol 1987; 88:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/42\">",
"      Stokes MB, Alpers CE. Combined membranous nephropathy and IgA nephropathy. Am J Kidney Dis 1998; 32:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/43\">",
"      Andrassy K, Waldherr R, Erb A, Ritz E. De novo glomerulonephritis in patients during remission from Wegener's granulomatosis. Clin Nephrol 1992; 38:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/44\">",
"      Bergmann J, Buchheidt D, Waldherr R, et al. IgA nephropathy and hodgkin's disease: a rare coincidence. Case report and literature review. Am J Kidney Dis 2005; 45:e16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/45\">",
"      Mak SK, Wong PN, Lo KY, Wong AK. Successful treatment of IgA nephropathy in association with low-grade B-cell lymphoma of the mucosa-associated lymphoid tissue type. Am J Kidney Dis 1998; 31:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/46\">",
"      Wilson FP, Nasr SH, Markowitz GS, et al. A destructive nasal lesion and glomerulonephritis. Kidney Int 2006; 69:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/47\">",
"      Hern&aacute;ndez JI, G&oacute;mez-Rom&aacute;n J, Rodrigo E, et al. Bronchiolitis obliterans and IgA nephropathy. A new cause of pulmonary-renal syndrome. Am J Respir Crit Care Med 1997; 156:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/48\">",
"      Hubert D, Beaufils M, Meyrier A. [Immunoglobulin A glomerular nephropathy associated with inflammatory colitis. Apropos of 2 cases]. Presse Med 1984; 13:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/49\">",
"      Hirsch DJ, Jindal KK, Trillo A, Cohen AD. Acute renal failure in Crohn's disease due to IgA nephropathy. Am J Kidney Dis 1992; 20:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/50\">",
"      Takemura T, Okada M, Yagi K, et al. An adolescent with IgA nephropathy and Crohn disease: pathogenetic implications. Pediatr Nephrol 2002; 17:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/51\">",
"      Forshaw MJ, Guirguis O, Hennigan TW. IgA nephropathy in association with Crohn's disease. Int J Colorectal Dis 2005; 20:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/52\">",
"      Neelakantappa K, Gallo GR, Baldwin DS. Proteinuria in IgA nephropathy. Kidney Int 1988; 33:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/53\">",
"      Hasbargen JA, Copley JB. Utility of skin biopsy in the diagnosis of IgA nephropathy. Am J Kidney Dis 1985; 6:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/54\">",
"      Suzuki H, Fan R, Zhang Z, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 2009; 119:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/55\">",
"      Glassock RJ. Analyzing antibody activity in IgA nephropathy. J Clin Invest 2009; 119:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/56\">",
"      Moldoveanu Z, Wyatt RJ, Lee JY, et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 2007; 71:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/57\">",
"      Roos A, van Kooten C. Underglycosylation of IgA in IgA nephropathy: more than a diagnostic marker? Kidney Int 2007; 71:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/58\">",
"      van Paassen P, van Breda Vriesman PJ, van Rie H, Tervaert JW. Signs and symptoms of thin basement membrane nephropathy: a prospective regional study on primary glomerular disease-The Limburg Renal Registry. Kidney Int 2004; 66:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1337/abstract/59\">",
"      Iseki K, Miyasato F, Uehara H, et al. Outcome study of renal biopsy patients in Okinawa, Japan. Kidney Int 2004; 66:914.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3112 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-77.94.48.4-CE85A84A2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_19_1337=[""].join("\n");
var outline_f1_19_1337=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Oxford classification of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cirrhosis and other forms of severe liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Celiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Minimal change disease and membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Granulomatosis with polyangiitis (Wegener's)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H103350371\">",
"      Indications for renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H103350402\">",
"      Tests of limited utility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3112\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3112|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/4/28745\" title=\"picture 1\">",
"      Focal GN Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/2/23599\" title=\"picture 2\">",
"      IgA nephropathy IF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/0/12297\" title=\"picture 3\">",
"      IgA nephropathy EM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27706?source=related_link\">",
"      Diagnosis and classification of renal disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=related_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18136?source=related_link\">",
"      Extrapulmonary manifestations of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/2/17445?source=related_link\">",
"      Glomerular hematuria: IgA; Alport; thin basement membrane nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21690?source=related_link\">",
"      Indications for and complications of renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4168?source=related_link\">",
"      Overview of kidney disease in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/48/20233?source=related_link\">",
"      Pathogenesis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/62/12257?source=related_link\">",
"      Patient information: IgA nephropathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9130?source=related_link\">",
"      Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis?source=related_link\">",
"      Renal manifestations of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12088?source=related_link\">",
"      Thin basement membrane nephropathy (benign familial hematuria)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42106?source=related_link\">",
"      Treatment and prognosis of IgA nephropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_19_1338="Clinical manifestations of primary hyperparathyroidism";
var content_f1_19_1338=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of primary hyperparathyroidism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/19/1338/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/19/1338/contributors\">",
"     Ghada El-Hajj Fuleihan, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/19/1338/contributors\">",
"     Shonni J Silverberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/19/1338/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/19/1338/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/19/1338/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/19/1338/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/19/1338/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common clinical presentation of primary hyperparathyroidism (PHPT) is asymptomatic hypercalcemia detected by routine biochemical screening. However, the presentation may be atypical and include a spectrum of disturbances in calcium homeostasis, ranging from symptomatic severe hypercalcemia (parathyroid crisis) to normocalcemic primary hyperparathyroidism.",
"   </p>",
"   <p>",
"    There are geographical differences in the clinical manifestations of PHPT that may be explained, at least in part, by ascertainment bias or vitamin D nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In countries where hypovitaminosis D is prevalent, PHPT may be characterized by overt severe clinical bone and stone disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations that are directly related to PHPT will be reviewed here. Symptoms and signs (gastrointestinal, neuromuscular, renal, and psychological) that are likely related to hypercalcemia are also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=see_link\">",
"     \"Clinical manifestations of hypercalcemia\"",
"    </a>",
"    .) It should be recognized, however, that the distinction is to some extent arbitrary.",
"   </p>",
"   <p>",
"    The clinical manifestations of the familial forms of PHPT and of parathyroid cancer, and the diagnosis and management of PHPT are also reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=see_link\">",
"     \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13688?source=see_link\">",
"     \"Parathyroid carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link\">",
"     \"Management of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biochemical screening tests that include measurements of serum calcium currently account for the identification of at least 80 percent of patients with primary hyperparathyroidism (PHPT) in western countries (",
"    <a class=\"graphic graphic_figure graphicRef62696 \" href=\"UTD.htm?42/31/43517\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/4\">",
"     4",
"    </a>",
"    ]. These patients are usually asymptomatic and have mild and sometimes only intermittent hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In most asymptomatic patients, the mean serum calcium concentration is less than 1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.25",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    above the upper limit of the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/5\">",
"     5",
"    </a>",
"    ]. Occasionally, patients are normocalcemic, and elevated parathyroid hormone levels are detected through a work-up of low bone density [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. There are few data on the clinical manifestations of this entity, termed normocalcemic primary hyperparathyroidism. Normocalcemic primary hyperparathyroidism is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\", section on 'Normocalcemic primary hyperparathyroidism versus secondary hyperparathyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients with presumed asymptomatic PHPT, when carefully questioned, have nonspecific symptoms, such as fatigue, weakness, anorexia, mild depression, and mild cognitive or neuromuscular dysfunction, and others simply miss work often [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. With time, some patients with true asymptomatic PHPT may develop clinical manifestations of PHPT, including skeletal manifestations, nephrocalcinosis, or kidney stones. Thus, the differentiation between symptomatic and asymptomatic PHPT is not always clear-cut [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classical symptoms and signs of PHPT reflect the combined effects of increased PTH secretion (",
"    <a class=\"graphic graphic_table graphicRef69796 \" href=\"UTD.htm?3/12/3275\">",
"     table 1",
"    </a>",
"    ) and hypercalcemia (",
"    <a class=\"graphic graphic_table graphicRef54647 \" href=\"UTD.htm?41/50/42795\">",
"     table 2",
"    </a>",
"    ). These are known as the \"bones, stones, abdominal moans and psychic groans.\" The abnormalities directly associated with hyperparathyroidism are nephrolithiasis and bone disease; both are due to prolonged PTH excess [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/4,13\">",
"     4,13",
"    </a>",
"    ]. Symptoms attributable to hypercalcemia include anorexia, nausea, constipation, polydipsia, and polyuria. Symptoms in PHPT are not necessarily related to serum calcium levels [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/14\">",
"     14",
"    </a>",
"    ]; however, they seem to be more common in patients in whom hypercalcemia develops rapidly. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Parathyroid crisis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although bone disease and stone disease are the universally accepted classical manifestations of PHPT, clinical parathyroid bone disease (osteitis fibrosa cystica) is rarely seen in the United States today (&lt;5 percent of patients), and the incidence of nephrolithiasis has declined over the last few decades. Nevertheless, nephrolithiasis remains the most common complication of PHPT, occurring in approximately 15 to 20 percent of newly diagnosed patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/4,13\">",
"     4,13",
"    </a>",
"    ]. In addition, classical manifestations of PHPT are still prevalent in developing countries. As an example, in a study of 79 patients (mean age 33 years) with primary hyperparathyroidism from Western India, skeletal manifestations (75.5 percent), renal calculi (40.5 percent), and proximal muscle weakness (45.5 percent) were the most common symptoms at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The geographical differences in the clinical manifestations of PHPT may be explained, at least in part, by the greater prevalence of vitamin D deficiency in some countries [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Vitamin D deficiency is common in patients with PHPT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/16\">",
"     16",
"    </a>",
"    ]. Individuals with vitamin D deficiency and hyperparathyroidism have more clinically significant disease, including larger adenomas, higher concentrations of PTH, increased bone turnover, and more frequent fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due to the significant prevalence of vitamin D insufficiency in individuals with PHPT, the Third International Workshop on Asymptomatic Primary Hyperparathyroidism recommends measuring 25OHD in all patients with PHPT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\", section on 'Vitamin D metabolites'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link&amp;anchor=H22#H22\">",
"     \"Management of primary hyperparathyroidism\", section on 'Treatment of concomitant vitamin D deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Osteitis fibrosa cystica",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic manifestation of PHPT bone disease is osteitis fibrosa cystica, which is characterized clinically by bone pain and radiographically by subperiosteal bone resorption on the radial aspect of the middle phalanges (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87019 \" href=\"UTD.htm?38/51/39730\">",
"     image 1",
"    </a>",
"    ), tapering of the distal clavicles (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87017 \" href=\"UTD.htm?16/62/17380\">",
"     image 2",
"    </a>",
"    ), a \"salt and pepper\" appearance of the skull (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87018 \" href=\"UTD.htm?26/57/27537\">",
"     image 3",
"    </a>",
"    ), bone cysts, and brown tumors of the long bones (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87016 \" href=\"UTD.htm?24/50/25377\">",
"     image 4",
"    </a>",
"    ). Brown tumors result from excess osteoclast activity and consist of collections of osteoclasts intermixed with fibrous tissue and poorly mineralized woven bone. The brown coloration is due to hemosiderin deposition.",
"   </p>",
"   <p>",
"    Osteitis fibrosa cystica is now very rare in the United States. It occurs more typically in patients with severe disease, especially those with parathyroid carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/4\">",
"     4",
"    </a>",
"    ]. In a review of 97 cases of mild PHPT, as an example, conventional radiography revealed signs of bone disease in only one patient [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/21\">",
"     21",
"    </a>",
"    ]. On the other hand, bone disease remains a major problem in patients with secondary hyperparathyroidism due to chronic renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nephrolithiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important renal manifestations of PHPT are nephrolithiasis, hypercalciuria, nephrocalcinosis, chronic renal insufficiency, and several abnormalities in renal tubular function, in particular, decreased concentrating ability (",
"    <a class=\"graphic graphic_table graphicRef65839 \" href=\"UTD.htm?2/15/2299\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nephrolithiasis occurs in approximately 15 to 20 percent of patients with PHPT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/4\">",
"     4",
"    </a>",
"    ]; conversely, about 5 percent of patients with nephrolithiasis have hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/23\">",
"     23",
"    </a>",
"    ]. Nephrocalcinosis is much less common [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17081?source=see_link\">",
"     \"Nephrocalcinosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among normocalcemic patients with nephrolithiasis, PHPT should be suspected if the serum calcium concentration is in the high-normal range, because the hypercalcemia may be intermittent and detected only by multiple measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/6,23,24\">",
"     6,23,24",
"    </a>",
"    ]. In one series of 48 patients with nephrolithiasis and PHPT, 30 (63 percent) had serum calcium concentrations between 10.2 and 11",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.55 and 2.75",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most stones in patients with PHPT are composed of calcium oxalate [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/23\">",
"     23",
"    </a>",
"    ], although a slightly alkaline urine may favor the precipitation of calcium phosphate stones. A contributing factor for stone formation in PHPT is hypercalciuria. Although PTH directly stimulates the distal tubular reabsorption of calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/25\">",
"     25",
"    </a>",
"    ], this effect is overshadowed by the increase in filtered calcium due to hypercalcemia, leading to increased urinary calcium excretion in 35 to 40 percent of patients with PHPT.",
"   </p>",
"   <p>",
"    However, urinary calcium excretion per gram creatinine does not necessarily differentiate patients with or without stones [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/13\">",
"     13",
"    </a>",
"    ]. This is likely due to the limited precision of a 24-hour urine calcium collection and to the complexity of factors that determine stone formation. Urinary calcium concentration is only one of at least six urinary risk factors that determine the urine saturation of the calcium salts that lead to calcium stone formation. It is for this reason that elevated levels of urinary calcium excretion are no longer, in and of itself, considered an indication for surgery in PHPT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of primary hyperparathyroidism\", section on 'Candidates for surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A high serum calcitriol concentration, caused by PTH stimulation of renal hydroxylation of 25-hydroxyvitamin D, may contribute to both hypercalciuria and stone formation. This was illustrated in a report of 50 patients with PHPT in which 19 of the 30 patients who had high serum calcitriol concentrations, hypercalciuria, and increased dietary calcium absorption had kidney stones, as compared with only 3 of 20 patients who had normal to high-normal serum calcitriol concentrations and normal urinary calcium excretion and dietary calcium absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/26\">",
"     26",
"    </a>",
"    ]. However, this distinction was not apparent in another series of 70 patients with mild PHPT, 18 percent of whom had kidney stones [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/27\">",
"     27",
"    </a>",
"    ]. There was no difference in serum PTH, calcium, or calcitriol concentrations between patients with and without kidney stones, but more of the kidney stone group had hypercalciuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Neuromuscular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complaints of weakness and fatigue are common among patients with PHPT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/11,28\">",
"     11,28",
"    </a>",
"    ]. In classical PHPT, a neuromuscular syndrome characterized by atrophy of type II muscle fibers was seen [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/29\">",
"     29",
"    </a>",
"    ]. However, that syndrome, as well as any objective evidence of myopathy or weakness, is rarely seen today [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some more severely affected patients, neuromuscular symptoms may improve after cure. In one report, muscle strength and fine motor movement increased four weeks after parathyroidectomy in all nine patients with PHPT, but not in a control group who underwent surgery for nodular goiter [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/31\">",
"     31",
"    </a>",
"    ]. However, these reports are limited by small sample sizes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Neuropsychiatric disturbances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurobehavioral symptoms have been recognized in patients with PHPT for almost seven decades and appear to be more prevalent in patients with PHPT than in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. These symptoms include lethargy, depressed mood, psychosis, decreased social interaction and cognitive dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/34\">",
"     34",
"    </a>",
"    ]. The exact prevalence of such abnormalities is not well defined due to the lack of rigorous assessment for symptoms in many studies, the small size of the studies, and the wide variations in the instruments used to assess such disturbances [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, in a case-control study comparing 39 postmenopausal women with mild PHPT with 89 postmenopausal controls without PHPT, symptom scores for depression and anxiety were higher, and performance on tests of verbal memory and nonverbal abstraction was worse in women with PHPT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/35\">",
"     35",
"    </a>",
"    ]. After parathyroidectomy, depressive symptoms, nonverbal abstraction, and some aspects of verbal memory significantly improved.",
"   </p>",
"   <p>",
"    Since 2002, three randomized clinical trials have been published, assessing the effect of parathyroidectomy versus nonintervention in mild PHPT on, among other things, neuropsychiatric symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. Data suggest modest differences, favoring surgical intervention. However, the differences are very small, not specific across the studies, and of uncertain clinical significance. These trials are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of primary hyperparathyroidism\", section on 'Neuropsychiatric'",
"    </a>",
"    .) The recommended list of criteria for surgical intervention in PHPT does not currently include neuropsychiatric symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/1,8\">",
"     1,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     OTHER MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H196421\">",
"    <span class=\"h2\">",
"     Skeletal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although classical bone disease osteitis fibrosa cystica is rare today, the skeleton remains very much an end organ in this disease. This is clear from studies of bone density and histomorphometry in primary hyperparathyroidism (PHPT).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Bone mineral density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PHPT may have decreased bone mineral density (BMD), in particular at more cortical sites (forearm and hip) as compared with more cancellous sites (spine). Randomized trials have demonstrated increased BMD following parathyroidectomy. Measurement of BMD is an essential part of the management of the disease, and BMD should be measured at the spine, hip, and distal one-third forearm sites. The degree of bone loss is reflective of the severity of hyperparathyroidism and is useful for making recommendations for parathyroid surgery or observation with monitoring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of primary hyperparathyroidism\", section on 'Bone disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H196737\">",
"    <span class=\"h3\">",
"     Bone histomorphometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classical histomorphometric profile of patients with hyperparathyroidism, the majority of whom have asymptomatic disease, shows thin cortices with preserved trabecular bone [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/39\">",
"     39",
"    </a>",
"    ]. This profile is more pronounced in patients with concomitant vitamin D deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the densitometric and histomorphometric studies, showing relative preservation of trabecular bone and thinning of cortical bone, it would be anticipated that fractures would be more common at cortical sites. However, most [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/41-45\">",
"     41-45",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/46\">",
"     46",
"    </a>",
"    ], studies have demonstrated an increased risk of vertebral fractures in patients with PHPT. In one of these reports of 407 patients with mild PHPT, there were 471 fractures at a mean follow-up of about 14 years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/45\">",
"     45",
"    </a>",
"    ]. The overall standardized fracture risk ratio was significantly increased, with a two- to threefold increase in risk of vertebral, distal forearm, and pelvic fractures. The significant predictors of fractures were age and female sex.",
"   </p>",
"   <p>",
"    The largest report of hip fracture was a population-based study of over 1800 patients with PHPT in Uppsala, Sweden [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/47\">",
"     47",
"    </a>",
"    ]. There was an increase in hip fracture in men, but not in women. In a retrospective review of the 28-year experience at the Mayo Clinic, risks of vertebral, Colles', rib and pelvic fractures were increased significantly, but the risk of hip fracture was increased only marginally [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of PHPT on fracture incidence appears related not only to on site-specific changes in areal bone density, but also to the effect of the disease on other factors related to bone quality [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/13\">",
"     13",
"    </a>",
"    ]. Excess parathyroid hormone would induce cortical thinning due to endosteal bone resorption, but would also increase periosteal apposition, thus increasing bone diameter. Decreased areal bone density would increase fracture risk, while increased bone diameter and preserved trabecular microarchitecture would protect against fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/13\">",
"     13",
"    </a>",
"    ]. Since fracture is not common in PHPT, prospective multicenter studies that capture site-specific fractures are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;PHPT may be associated with cardiovascular disease, as illustrated by the following findings in observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/48\">",
"     48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertension is common in patients with PHPT even among those with mild disease [",
"      <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/49-51\">",
"       49-51",
"      </a>",
"      ]. The causal nature of this relationship in those without multiple endocrine neoplasia is unclear, since hypertension does not improve with cure of PHPT.",
"     </li>",
"     <li>",
"      Several [",
"      <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/52-55\">",
"       52-55",
"      </a>",
"      ], but not all [",
"      <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/56,57\">",
"       56,57",
"      </a>",
"      ], observational studies have reported an association between PHPT and left ventricular hypertrophy and diastolic dysfunction. In one study, there was a small but significant decrease in left ventricular mass after surgical correction of the hyperparathyroidism, a finding that was most pronounced in patients with no history of hypertension, an effect that may be mediated by increased vascular stiffness [",
"      <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/58,59\">",
"       58,59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mean carotid intima-media thickness (IMT) was significantly higher in patients with mild PHPT compared with controls (0.96 versus 0.91 mm) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/60\">",
"       60",
"      </a>",
"      ]. In addition, an indirect measure of aortic stiffness [",
"      <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/59\">",
"       59",
"      </a>",
"      ] and carotid vascular stiffness [",
"      <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/60\">",
"       60",
"      </a>",
"      ] were associated with extent of PTH elevation, suggesting that vessel stiffness may be related to the severity of hyperparathyroidism. In adult populations, there is a moderate, graded positive relationship between carotid IMT and the presence of coronary atherosclerosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34394?source=see_link&amp;anchor=H10122160#H10122160\">",
"       \"Overview of the possible risk factors for cardiovascular disease\", section on 'Arterial intima-media thickness'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The available data are observational, and definitive evidence for an improvement in cardiovascular function post-parathyroidectomy is lacking. As an example, in a randomized trial of 116 patients with mild primary hyperparathyroidism, there was no observable effect of successful parathyroidectomy on blood pressure, markers of insulin resistance, adipokines, markers of inflammation, as surrogate cardiovascular markers, two years post-parathyroidectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/61\">",
"     61",
"    </a>",
"    ]. The only proven association between PHPT and cardiovascular disease is in patients with PHPT as part of MEN-2 with pheochromocytoma. The nature of cardiovascular involvement and the extent to which any abnormalities improve postoperatively need to be further elucidated before a cause-and-effect relationship can be established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link&amp;anchor=H6#H6\">",
"     \"Management of primary hyperparathyroidism\", section on 'Cardiovascular'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Body weight and abnormalities in glucose metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;A higher than normal frequency of impaired glucose tolerance and type 2 diabetes have been reported in some, but not all, studies of PHPT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/51,58,62,63\">",
"     51,58,62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with PHPT appear to be heavier than age-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/64\">",
"     64",
"    </a>",
"    ]. In a meta-analysis of 13 studies of PHPT, subjects with PHPT were on average 3.3 kg heavier than controls and body mass index (BMI), in the four studies that reported it, was 1.1",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    higher than controls [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/64\">",
"     64",
"    </a>",
"    ]. The increased body weight may contribute to the association of PHPT with cardiovascular disease, hypertension, and glucose intolerance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Rheumatologic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many rheumatologic abnormalities have been described in patients with classical symptomatic PHPT, but none of these are commonly seen in modern day disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/65\">",
"     65",
"    </a>",
"    ]. They include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperuricemia and gout.",
"     </li>",
"     <li>",
"      Pseudogout with pyrophosphate crystals into the joint [",
"      <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/66-69\">",
"       66-69",
"      </a>",
"      ]. Calcification of articular cartilage (chondrocalcinosis), most commonly affecting the wrists and knees, is more commonly reported than gout itself [",
"      <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/68,69\">",
"       68,69",
"      </a>",
"      ]. Pseudogout may also be seen soon after parathyroidectomy. The mechanism for this is unclear. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=see_link\">",
"       \"Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe classical PHPT is associated with increased mortality, primarily due to cardiovascular disease. However, the impact of milder PHPT on cardiovascular mortality is uncertain. Excess mortality, mostly due to cardiovascular disease, has been reported in a number of Scandinavian studies of patients with PHPT (RR ranging from 1.2 to 2.0) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/70-74\">",
"     70-74",
"    </a>",
"    ]. The higher mortality rate declines with time from parathyroidectomy, but does persist after surgical cure. This suggests that the disease may cause enduring damage to the cardiovascular system. There has been some controversy as to whether this excess in mortality is related to disease severity as assessed by serum calcium levels. Whereas in one study excess mortality was best predicted by the serum calcium concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/71\">",
"     71",
"    </a>",
"    ], in two other studies excess mortality was noted even in the presence of mild hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/72,75\">",
"     72,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest study to date on this subject was conducted on 10,995 Swedish patients with PHPT who underwent parathyroidectomy between 1958 and 1997 (identified through the Cancer and Causes of Death Registries) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/76\">",
"     76",
"    </a>",
"    ]. Mortality, primarily cardiovascular, was increased (standard mortality ratio of 1.2) in the overall group and persisted up to 15 years post-parathyroidectomy. It was noted in both genders and all age groups. However, in the subset of 6386 patients operated on between 1985 and 1997, there was no increase in mortality. Possible speculations for the decreased mortality in the latter subset include a milder clinical presentation or earlier surgical intervention. Surprisingly, a previously published Swedish study conducted on 4461 patients operated in the same period, between 1987 and 1994, and using the same national Swedish registries, observed an increased mortality (RR 1.7 for men and 1.85 for women) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/72\">",
"     72",
"    </a>",
"    ]. The reason for the discrepancy between the two Swedish studies is unclear.",
"   </p>",
"   <p>",
"    Mortality data looking exclusively at patients with the milder, less symptomatic disease that we see most commonly today are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. One study, which followed patients for up to 15 years (mean calcium 11.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.8",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    did not find decreased survival compared to age- and gender-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/77\">",
"     77",
"    </a>",
"    ]. In another report of 435 consecutive patients (from Rochester, Minnesota) with PHPT, 71 percent of whom were managed without surgery, overall (RR 0.69, 95% CI 0.57-0.83) and cardiovascular (RR 0.60, 95% CI 0.45-0.79) mortality were reduced compared with other Minnesota residents [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/78\">",
"     78",
"    </a>",
"    ]. However, in a multivariate analysis, higher calcium levels (&ge;11.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.8 to",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    were associated with worse survival.",
"   </p>",
"   <p>",
"    Further study is needed to determine whether cardiovascular mortality is truly increased in patients with PHPT and whether that risk is affected by disease severity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    timing of surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/1,8\">",
"     1,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link\">",
"     \"Management of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data on whether PHPT is more common in patients with cancer",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    whether it is associated with an increased risk of cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/76,78,80-83\">",
"     76,78,80-83",
"    </a>",
"    ]. Several studies suggest a small increase in risk of death from cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/76,80,81\">",
"     76,80,81",
"    </a>",
"    ], even after parathyroidectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. In contrast, cancer-related mortality was lower than expected in an unselected cohort of patients with PHPT in the community (many of whom did not undergo surgery) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PHPT is usually first suspected by the finding of an elevated serum calcium concentration. A frankly elevated PTH concentration or a PTH value in the upper half of the normal range in the setting of hypercalcemia is likely the result of PHPT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most patients, serum calcium and PTH levels remain stable, although they may increase over time in a small subset (&lt;5 percent) of subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. Some patients with PHPT may have normal serum calcium levels (normocalcemic primary hyperparathyroidism). However, in order to make the diagnosis of normocalcemic PHPT, secondary causes of hyperparathyroidism must first be ruled out and the PTH concentration must be frankly elevated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\", section on 'Normocalcemic primary hyperparathyroidism versus secondary hyperparathyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other laboratory findings may include the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of renal insufficiency in PHPT is related to the degree and duration of hypercalcemia. Mild hypercalcemia is rarely associated with renal insufficiency. In randomized trials of two to three years duration, there is little evidence that renal function deteriorates in patients with mild chronic hypercalcemia due to PHPT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link&amp;anchor=H9#H9\">",
"     \"Management of primary hyperparathyroidism\", section on 'Biochemical abnormalities'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations of hypercalcemia\", section on 'Renal insufficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hypophosphatemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients with mild PHPT, phosphate levels are not frankly low, but are instead in the lower half of the normal range. In some patients with more severe disease, serum phosphate concentrations are low because PTH inhibits the proximal tubular reabsorption of phosphate, leading to increased phosphate excretion. The decrease in reabsorption is due to reduced activity of the sodium-phosphate cotransporter in the luminal membrane, so that entry of filtered phosphate into the tubular cells, and therefore its return to the systemic circulation, are decreased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Magnesium balance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal tubular reabsorption of magnesium is stimulated by PTH but inhibited by hypercalcemia. The effects of the hypercalcemia on magnesium excretion may be mediated via calcium-sensing receptors in the thick ascending loop of Henle. Overall, magnesium excretion tends to be slightly increased and a few patients have mild hypomagnesemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=see_link\">",
"     \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Acid-base balance",
"    </span>",
"    &nbsp;&mdash;&nbsp;High concentrations of PTH inhibit proximal tubular bicarbonate reabsorption, which tends to cause a mild metabolic acidosis. However, this effect is usually counterbalanced by the alkali liberated as a result of increases in bone resorption and in tubular reabsorption of bicarbonate caused by hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. Thus, metabolic acidosis is unusual in PHPT unless serum PTH concentrations are very high or the patient has coexistent renal insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe PHPT may have a normochromic normocytic anemia that responds to parathyroidectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/88\">",
"     88",
"    </a>",
"    ]. The mechanism is unclear, but marrow fibrosis may be important [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. In patients with mild disease, anemia should not be attributed to coexisting PHPT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Monoclonal gammopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There may be an association between PHPT and monoclonal gammopathy, although data are conflicting. While the prevalence of monoclonal gammopathy in the general adult population is approximately 1 percent, estimates in patients with PHPT have ranged from 1 to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/90-93\">",
"     90-93",
"    </a>",
"    ]. This may be an association limited to those with severe disease. As an example, the highest prevalence (10 percent) was reported in a prospective study of 100 cases with severe PHPT (median calcium of 12",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and PTH levels of 200",
"    <span class=\"nowrap\">",
"     pg/mL),",
"    </span>",
"    compared with 2 to 3 percent in two control groups (age- and gender-matched) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/93\">",
"     93",
"    </a>",
"    ]. Of the 10 patients with monoclonal gammopathy, two were discovered to have multiple myeloma.",
"   </p>",
"   <p>",
"    There are also several single case reports of concomitant PHPT and multiple myeloma. Whether this truly represents an increased prevalence of this comorbidity remains unknown. However, it has been suggested that until further data are available, a serum protein electrophoresis should be considered in patients with PHPT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PHYSICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no specific physical findings of PHPT. Parathyroid adenomas are rarely palpable, and if a neck mass is palpated in a patient with PHPT, the diagnosis is more likely to be thyroid nodule or parathyroid carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13688?source=see_link\">",
"     \"Parathyroid carcinoma\"",
"    </a>",
"    .) Band keratopathy (deposition of calcium phosphate in the exposed areas of the cornea) is rare and occurs only when serum calcium and phosphate concentrations are both high. A slit-lamp examination is usually needed to detect the keratopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PARATHYROID CRISIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parathyroid crisis is rare; the risk in a patient with known PHPT was estimated at 1 to 2 percent in two long-term studies of untreated patients with mild PHPT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. Parathyroid crisis is characterized by severe hypercalcemia, with the serum calcium concentration usually above 15",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and marked symptoms of hypercalcemia, in particular, central nervous system dysfunction. In some cases, the syndrome occurs in patients with previously documented PHPT that is not severe. In others, it is the first evidence of parathyroid disease.",
"   </p>",
"   <p>",
"    In a review of 48 cases of parathyroid crisis, the numbers of women and men were similar; the mean age was 55 years and the mean serum calcium concentration was 17.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.4",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/96\">",
"     96",
"    </a>",
"    ]. Of the 38 patients for whom clinical information was available, the following characteristics were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Changes in mental status were common; 20 patients were comatose and the remaining 18 were confused.",
"     </li>",
"     <li>",
"      Sixty-nine percent had bone disease, as assessed by plain radiography or radionuclide bone scan.",
"     </li>",
"     <li>",
"      Fifty-three percent had nephrolithiasis and 50 percent had both bone disease and nephrolithiasis.",
"     </li>",
"     <li>",
"      Serum PTH concentrations were on average",
"      <strong>",
"       20 times",
"      </strong>",
"      the upper limit of normal.",
"     </li>",
"     <li>",
"      One-fourth of the patients were known to have had hypercalcemia at some time in the preceding 10 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other clinical problems included severe abdominal pain, nausea, vomiting, peptic ulcer, and pancreatitis.",
"   </p>",
"   <p>",
"    Another report compared 54 patients with parathyroid crisis to 460 patients treated at the same hospital for PHPT without hypercalcemic crisis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/97\">",
"     97",
"    </a>",
"    ]. There were more patients younger than 40 years old among those with parathyroid crisis (20 versus 5 percent).",
"   </p>",
"   <p>",
"    The mechanism for the development of parathyroid crisis is not known, but may be related to an intercurrent illness (often of a life-threatening nature), volume depletion, or infarction of a parathyroid adenoma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/19/1338/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/6/2147?source=see_link\">",
"       \"Patient information: Primary hyperparathyroidism (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/52/29507?source=see_link\">",
"       \"Patient information: Primary hyperparathyroidism (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common clinical presentation of primary hyperparathyroidism (PHPT) in western populations is asymptomatic hypercalcemia detected by routine biochemical screening. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Asymptomatic primary hyperparathyroidism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The classical symptoms and signs of PHPT, such as osteitis fibrosa cystica and nephrolithiasis, are due to prolonged excessive PTH secretion and hypercalcemia. Although osteitis fibrosa cystica is rarely seen in the United States and Europe, it is still prevalent in developing countries. The geographical differences in the clinical manifestations of PHPT may be explained, at least in part, by the greater prevalence of vitamin D deficiency in some countries. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Classical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neurobehavioral and cognitive complaints may be more prevalent in patients with PHPT than in the general population. However, the nonspecific nature of these symptoms makes it difficult to ascribe a particular complaint to PHPT in a given patient. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Neuropsychiatric disturbances'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with PHPT may have decreased bone mineral density (BMD), in particular at more cortical sites (forearm and hip) as compared with more cancellous sites (spine). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Other manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The nature of cardiovascular involvement and the impact of PHPT on cardiovascular mortality require further elucidation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Other manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/1\">",
"      Bilezikian JP, Khan AA, Potts JT Jr, Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009; 94:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/2\">",
"      Bilezikian JP, Meng X, Shi Y, Silverberg SJ. Primary hyperparathyroidism in women: a tale of two cities--New York and Beijing. Int J Fertil Womens Med 2000; 45:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/3\">",
"      Mishra SK, Agarwal G, Kar DK, et al. Unique clinical characteristics of primary hyperparathyroidism in India. Br J Surg 2001; 88:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/4\">",
"      Silverberg SJ, Bilezikian JP. Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81:2036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/5\">",
"      Bilezikian JP, Silverberg SJ. Clinical practice. Asymptomatic primary hyperparathyroidism. N Engl J Med 2004; 350:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/6\">",
"      Siperstein AE, Shen W, Chan AK, et al. Normocalcemic hyperparathyroidism. Biochemical and symptom profiles before and after surgery. Arch Surg 1992; 127:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/7\">",
"      Lowe H, McMahon DJ, Rubin MR, et al. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 2007; 92:3001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/8\">",
"      Silverberg SJ, Lewiecki EM, Mosekilde L, et al. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009; 94:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/9\">",
"      Perrier ND. Asymptomatic hyperparathyroidism: a medical misnomer? Surgery 2005; 137:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/10\">",
"      Lundgren E, Szabo E, Ljunghall S, et al. Population based case-control study of sick leave in postmenopausal women before diagnosis of hyperparathyroidism. BMJ 1998; 317:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/11\">",
"      Lundgren E, Ljunghall S, Akerstr&ouml;m G, et al. Case-control study on symptoms and signs of \"asymptomatic\" primary hyperparathyroidism. Surgery 1998; 124:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/12\">",
"      Chan AK, Duh QY, Katz MH, et al. Clinical manifestations of primary hyperparathyroidism before and after parathyroidectomy. A case-control study. Ann Surg 1995; 222:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/13\">",
"      Bilezikian JP, Brandi ML, Rubin M, Silverberg SJ. Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Intern Med 2005; 257:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/14\">",
"      Harrison BJ, Wheeler MH. Asymptomatic primary hyperparathyroidism. World J Surg 1991; 15:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/15\">",
"      Gopal RA, Acharya SV, Bandgar T, et al. Clinical profile of primary hyperparathyroidism from western India: a single center experience. J Postgrad Med 2010; 56:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/16\">",
"      Boudou P, Ibrahim F, Cormier C, et al. A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism. J Endocrinol Invest 2006; 29:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/17\">",
"      Rao DS, Honasoge M, Divine GW, et al. Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab 2000; 85:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/18\">",
"      Silverberg SJ, Shane E, Dempster DW, Bilezikian JP. The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med 1999; 107:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/19\">",
"      Kandil E, Tufaro AP, Carson KA, et al. Correlation of plasma 25-hydroxyvitamin D levels with severity of primary hyperparathyroidism and likelihood of parathyroid adenoma localization on sestamibi scan. Arch Otolaryngol Head Neck Surg 2008; 134:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/20\">",
"      Eastell R, Arnold A, Brandi ML, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009; 94:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/21\">",
"      Bilezikian JP, Silverberg SJ, Shane E, et al. Characterization and evaluation of asymptomatic primary hyperparathyroidism. J Bone Miner Res 1991; 6 Suppl 2:S85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/22\">",
"      Peacock M. Primary hyperparathyroidism and the kidney: biochemical and clinical spectrum. J Bone Miner Res 2002; 17 Suppl 2:N87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/23\">",
"      Parks J, Coe F, Favus M. Hyperparathyroidism in nephrolithiasis. Arch Intern Med 1980; 140:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/24\">",
"      Yendt ER, Gagne RJ. Detection of primary hyperparathyroidism, with special reference to its occurrence in hypercalciuric females with \"normal\" or borderline serum calcium. Can Med Assoc J 1968; 98:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/25\">",
"      Gesek FA, Friedman PA. On the mechanism of parathyroid hormone stimulation of calcium uptake by mouse distal convoluted tubule cells. J Clin Invest 1992; 90:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/26\">",
"      Broadus AE, Horst RL, Lang R, et al. The importance of circulating 1,25-dihydroxyvitamin D in the pathogenesis of hypercalciuria and renal-stone formation in primary hyperparathyroidism. N Engl J Med 1980; 302:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/27\">",
"      Silverberg SJ, Shane E, Jacobs TP, et al. Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am J Med 1990; 89:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/28\">",
"      Mallette LE, Bilezikian JP, Heath DA, Aurbach GD. Primary hyperparathyroidism: clinical and biochemical features. Medicine (Baltimore) 1974; 53:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/29\">",
"      Patten BM, Bilezikian JP, Mallette LE, et al. Neuromuscular disease in primary hyperparathyroidism. Ann Intern Med 1974; 80:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/30\">",
"      Turken SA, Cafferty M, Silverberg SJ, et al. Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. Am J Med 1989; 87:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/31\">",
"      Chou FF, Sheen-Chen SM, Leong CP. Neuromuscular recovery after parathyroidectomy in primary hyperparathyroidism. Surgery 1995; 117:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/32\">",
"      McAllion SJ, Paterson CR. Psychiatric morbidity in primary hyperparathyroidism. Postgrad Med J 1989; 65:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/33\">",
"      Joborn C, Hetta J, Johansson H, et al. Psychiatric morbidity in primary hyperparathyroidism. World J Surg 1988; 12:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/34\">",
"      Coker LH, Rorie K, Cantley L, et al. Primary hyperparathyroidism, cognition, and health-related quality of life. Ann Surg 2005; 242:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/35\">",
"      Walker MD, McMahon DJ, Inabnet WB, et al. Neuropsychological features in primary hyperparathyroidism: a prospective study. J Clin Endocrinol Metab 2009; 94:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/36\">",
"      Bollerslev J, Jansson S, Mollerup CL, et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab 2007; 92:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/37\">",
"      Ambrogini E, Cetani F, Cianferotti L, et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab 2007; 92:3114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/38\">",
"      Rao DS, Phillips ER, Divine GW, Talpos GB. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 2004; 89:5415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/39\">",
"      Parisien M, Mellish RW, Silverberg SJ, et al. Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis. J Bone Miner Res 1992; 7:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/40\">",
"      Stein EM, Dempster DW, Udesky J, et al. Vitamin D deficiency influences histomorphometric features of bone in primary hyperparathyroidism. Bone 2011; 48:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/41\">",
"      De Geronimo S, Romagnoli E, Diacinti D, et al. The risk of fractures in postmenopausal women with primary hyperparathyroidism. Eur J Endocrinol 2006; 155:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/42\">",
"      Dauphine RT, Riggs BL, Scholz DA. Back pain and vertebral crush fractures: an unemphasized mode of presentation for primary hyperparathyroidism. Ann Intern Med 1975; 83:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/43\">",
"      Kenny AM, MacGillivray DC, Pilbeam CC, et al. Fracture incidence in postmenopausal women with primary hyperparathyroidism. Surgery 1995; 118:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/44\">",
"      Melton, LJ 3rd, Atkinson, EJ, O'Fallon, WM, Heath, H 3rd. Risk of age-related fractures in patients with primary hyperparathyroidism. Arch Intern Med 1992; 152:2269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/45\">",
"      Khosla S, Melton LJ 3rd, Wermers RA, et al. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 1999; 14:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/46\">",
"      Wilson RJ, Rao S, Ellis B, et al. Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures. Ann Intern Med 1988; 109:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/47\">",
"      Larsson K, Ljunghall S, Krusemo UB, et al. The risk of hip fractures in patients with primary hyperparathyroidism: a population-based cohort study with a follow-up of 19 years. J Intern Med 1993; 234:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/48\">",
"      Andersson P, Rydberg E, Willenheimer R. Primary hyperparathyroidism and heart disease--a review. Eur Heart J 2004; 25:1776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/49\">",
"      Lind L, Hvarfner A, Palm&eacute;r M, et al. Hypertension in primary hyperparathyroidism in relation to histopathology. Eur J Surg 1991; 157:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/50\">",
"      Lind L, Ljunghall S. Pre-operative evaluation of risk factors for complications in patients with primary hyperparathyroidism. Eur J Clin Invest 1995; 25:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/51\">",
"      Lind L, Jacobsson S, Palm&eacute;r M, et al. Cardiovascular risk factors in primary hyperparathyroidism: a 15-year follow-up of operated and unoperated cases. J Intern Med 1991; 230:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/52\">",
"      Stefenelli T, Abela C, Frank H, et al. Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up. J Clin Endocrinol Metab 1997; 82:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/53\">",
"      N&auml;ppi S, Saha H, Virtanen V, et al. Left ventricular structure and function in primary hyperparathyroidism before and after parathyroidectomy. Cardiology 2000; 93:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/54\">",
"      Nilsson IL, Aberg J, Rastad J, Lind L. Left ventricular systolic and diastolic function and exercise testing in primary hyperparathyroidism-effects of parathyroidectomy. Surgery 2000; 128:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/55\">",
"      Piovesan A, Molineri N, Casasso F, et al. Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clin Endocrinol (Oxf) 1999; 50:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/56\">",
"      Barletta G, De Feo ML, Del Bene R, et al. Cardiovascular effects of parathyroid hormone: a study in healthy subjects and normotensive patients with mild primary hyperparathyroidism. J Clin Endocrinol Metab 2000; 85:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/57\">",
"      Walker MD, Fleischer JB, Di Tullio MR, et al. Cardiac structure and diastolic function in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2010; 95:2172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/58\">",
"      Smith JC, Page MD, John R, et al. Augmentation of central arterial pressure in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2000; 85:3515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/59\">",
"      Rubin MR, Maurer MS, McMahon DJ, et al. Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90:3326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/60\">",
"      Walker MD, Fleischer J, Rundek T, et al. Carotid vascular abnormalities in primary hyperparathyroidism. J Clin Endocrinol Metab 2009; 94:3849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/61\">",
"      Bollerslev J, Rosen T, Mollerup CL, et al. Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2009; 94:2255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/62\">",
"      Procopio M, Magro G, Cesario F, et al. The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed Type 2 diabetes mellitus in primary hyperparathyroidism. Diabet Med 2002; 19:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/63\">",
"      Valdemarsson S, Lindblom P, Bergenfelz A. Metabolic abnormalities related to cardiovascular risk in primary hyperparathyroidism: effects of surgical treatment. J Intern Med 1998; 244:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/64\">",
"      Bolland MJ, Grey AB, Gamble GD, Reid IR. Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J Clin Endocrinol Metab 2005; 90:1525.",
"     </a>",
"    </li>",
"    <li>",
"     Rubin MR, Silverberg SJ, Bilezikian JP. Primary hyperparathyroidism: Rheumatologic manifestations and bone disease. In: Bone Disease in Rheumatology, Maricic M, Gluck OS (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.190.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/66\">",
"      Helliwell M. [Rheumatic symptoms in primary hyperparathyroidism]. Postgrad Med J 1983; 59:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/67\">",
"      Bilezikian JP, Connor TB, Aptekar R, et al. Pseudogout after parathyroidectomy. Lancet 1973; 1:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/68\">",
"      Rynes RI, Merzig EG. Calcium pyrophosphate crystal deposition disease and hyperparathyroidism: a controlled, prospective study. J Rheumatol 1978; 5:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/69\">",
"      Alexander GM, Dieppe PA, Doherty M, Scott DG. Pyrophosphate arthropathy: a study of metabolic associations and laboratory data. Ann Rheum Dis 1982; 41:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/70\">",
"      Palmer M, Adami HO, Bergstr&ouml;m R, et al. Survival and renal function in untreated hypercalcaemia. Population-based cohort study with 14 years of follow-up. Lancet 1987; 1:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/71\">",
"      Leifsson BG, Ahr&eacute;n B. Serum calcium and survival in a large health screening program. J Clin Endocrinol Metab 1996; 81:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/72\">",
"      Hedb&auml;ck G, Od&eacute;n A. Increased risk of death from primary hyperparathyroidism--an update. Eur J Clin Invest 1998; 28:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/73\">",
"      Hedb&auml;ck G, Tisell LE, Bengtsson BA, et al. Premature death in patients operated on for primary hyperparathyroidism. World J Surg 1990; 14:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/74\">",
"      Palm&eacute;r M, Adami HO, Bergstr&ouml;m R, et al. Mortality after surgery for primary hyperparathyroidism: a follow-up of 441 patients operated on from 1956 to 1979. Surgery 1987; 102:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/75\">",
"      Lundgren E, Lind L, Palm&eacute;r M, et al. Increased cardiovascular mortality and normalized serum calcium in patients with mild hypercalcemia followed up for 25 years. Surgery 2001; 130:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/76\">",
"      Nilsson IL, Yin L, Lundgren E, et al. Clinical presentation of primary hyperparathyroidism in Europe--nationwide cohort analysis on mortality from nonmalignant causes. J Bone Miner Res 2002; 17 Suppl 2:N68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/77\">",
"      S&ouml;reide JA, van Heerden JA, Grant CS, et al. Survival after surgical treatment for primary hyperparathyroidism. Surgery 1997; 122:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/78\">",
"      Wermers RA, Khosla S, Atkinson EJ, et al. Survival after the diagnosis of hyperparathyroidism: a population-based study. Am J Med 1998; 104:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/79\">",
"      Yu N, Donnan PT, Leese GP. A record linkage study of outcomes in patients with mild primary hyperparathyroidism: the Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxf) 2011; 75:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/80\">",
"      Palm&eacute;r M, Adami HO, Krusemo UB, Ljunghall S. Increased risk of malignant diseases after surgery for primary hyperparathyroidism. A nationwide cohort study. Am J Epidemiol 1988; 127:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/81\">",
"      Pickard AL, Gridley G, Mellemkjae L, et al. Hyperparathyroidism and subsequent cancer risk in Denmark. Cancer 2002; 95:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/82\">",
"      Michels KB, Xue F, Brandt L, Ekbom A. Hyperparathyroidism and subsequent incidence of breast cancer. Int J Cancer 2004; 110:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/83\">",
"      Tanaka Y. Primary hyperparathyroidism with breast carcinoma. Breast Cancer 2010; 17:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/84\">",
"      Silverberg SJ, Shane E, Jacobs TP, et al. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999; 341:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/85\">",
"      Yu N, Leese GP, Smith D, Donnan PT. The natural history of treated and untreated primary hyperparathyroidism: the parathyroid epidemiology and audit research study. QJM 2011; 104:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/86\">",
"      Hulter HN, Peterson JC. Acid-base homeostasis during chronic PTH excess in humans. Kidney Int 1985; 28:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/87\">",
"      Sutton RA, Wong NL, Dirks JH. Effects of metabolic acidosis and alkalosis on sodium and calcium transport in the dog kidney. Kidney Int 1979; 15:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/88\">",
"      Boxer M, Ellman L, Geller R, Wang CA. Anemia in primary hyperparathyroidism. Arch Intern Med 1977; 137:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/89\">",
"      Meytes D, Bogin E, Ma A, et al. Effect of parathyroid hormone on erythropoiesis. J Clin Invest 1981; 67:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/90\">",
"      Johansson H, Werner I. Letter: Dysproteinemia, malignancy, and hyperparathyroidism. Ann Intern Med 1975; 83:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/91\">",
"      Mundis RJ, Kyle RA. Primary hyperparathyroidism and monoclonal gammopathy of undetermined significance. Am J Clin Pathol 1982; 77:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/92\">",
"      Rao DS, Antonelli R, Kane KR, et al. Primary hyperparathyroidism and monoclonal gammopathy. Henry Ford Hosp Med J 1991; 39:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/93\">",
"      Arnulf B, Bengoufa D, Sarfati E, et al. Prevalence of monoclonal gammopathy in patients with primary hyperparathyroidism: a prospective study. Arch Intern Med 2002; 162:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/94\">",
"      Corlew, DS, Bryda, SL, Braley, EL, et al. Observations on the course of untreated primary hyperparathyroidism. Surgery 1985; 98:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/95\">",
"      Scholz DA, Purnell DC. Asymptomatic primary hyperparathyroidism. 10-year prospective study. Mayo Clin Proc 1981; 56:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/96\">",
"      Fitzpatrick LA, Bilezikian JP. Acute primary hyperparathyroidism. Am J Med 1987; 82:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/19/1338/abstract/97\">",
"      Bondeson AG, Bondeson L, Thompson NW. Clinicopathological peculiarities in parathyroid disease with hypercalcaemic crisis. Eur J Surg 1993; 159:613.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2031 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-4BCC47CC64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_19_1338=[""].join("\n");
var outline_f1_19_1338=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Osteitis fibrosa cystica",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nephrolithiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Neuromuscular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Neuropsychiatric disturbances",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OTHER MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H196421\">",
"      Skeletal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Bone mineral density",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H196737\">",
"      - Bone histomorphometry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Body weight and abnormalities in glucose metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Rheumatologic manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Magnesium balance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Acid-base balance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Monoclonal gammopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PHYSICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PARATHYROID CRISIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2031\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2031|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/51/39730\" title=\"diagnostic image 1\">",
"      Osteitis fibrosa cystica findings on x-ray of the phalanges",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/62/17380\" title=\"diagnostic image 2\">",
"      Osteitis fibrosa cystica x-rays of the phalanges and clavicles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/57/27537\" title=\"diagnostic image 3\">",
"      Osteitis fibrosa cystica findings on skull x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/50/25377\" title=\"diagnostic image 4\">",
"      Brown tumors of pelvic bones findings on CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2031|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/31/43517\" title=\"figure 1\">",
"      Presentation of hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2031|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/12/3275\" title=\"table 1\">",
"      Sx of hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/50/42795\" title=\"table 2\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/15/2299\" title=\"table 3\">",
"      Renal sx in hyperparathyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=related_link\">",
"      Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=related_link\">",
"      Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=related_link\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=related_link\">",
"      Diagnosis and differential diagnosis of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=related_link\">",
"      Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=related_link\">",
"      Management of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17081?source=related_link\">",
"      Nephrocalcinosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34394?source=related_link\">",
"      Overview of the possible risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13688?source=related_link\">",
"      Parathyroid carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/52/29507?source=related_link\">",
"      Patient information: Primary hyperparathyroidism (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/6/2147?source=related_link\">",
"      Patient information: Primary hyperparathyroidism (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_19_1339="Features juvenile HD";
var content_f1_19_1339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F61297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F61297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of juvenile Huntington disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Rigidity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bradykinesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myoclonus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spasticity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebellar abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minimal chorea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cognitive and behavioral dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epilepsy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_19_1339=[""].join("\n");
var outline_f1_19_1339=null;
var title_f1_19_1340="Causes of amenorrhea";
var content_f1_19_1340=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F59801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F59801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of primary and secondary amenorrhea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Abnormality",
"       </td>",
"       <td class=\"subtitle1\">",
"        Causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Anatomic abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"5\">",
"        Congenital abnormality in Mullerian development*",
"       </td>",
"       <td>",
"        Isolated defect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Androgen insensitivity&nbsp;syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-Alpha-reductase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vanishing testes syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Defect in testis determining factor gene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Congenital defect of urogenital sinus development*",
"       </td>",
"       <td>",
"        Agenesis of lower vagina",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imperforate hymen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Acquired ablation or scarring of endometrium",
"       </td>",
"       <td>",
"        Asherman's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Disorders of the hypothalamic-pituitary-ovarian axis&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Hypothalamic dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Pituitary dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Ovarian dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Other",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Present as primary amenorrhea only.",
"     <br>",
"      &bull; The multiple causes of hormonal dysfunction are listed on the next table.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_19_1340=[""].join("\n");
var outline_f1_19_1340=null;
var title_f1_19_1341="Signs of nutritional deficiency";
var content_f1_19_1341=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physical signs of selected nutritional deficiency states",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Signs",
"      </td>",
"      <td class=\"subtitle1\">",
"       Deficiencies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"5\">",
"       Hair",
"      </td>",
"      <td>",
"       Alopecia",
"      </td>",
"      <td>",
"       Protein-energy malnutrition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Brittle",
"      </td>",
"      <td>",
"       Biotin, Protein-energy malnutrition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Color change",
"      </td>",
"      <td>",
"       Protein-energy malnutrition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dryness",
"      </td>",
"      <td>",
"       Vitamins E and A",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Easy pluckability",
"      </td>",
"      <td>",
"       Protein-energy malnutrition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"9\">",
"       Skin",
"      </td>",
"      <td>",
"       Acneiform lesions",
"      </td>",
"      <td>",
"       Vitamin A",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Follicular keratosis",
"      </td>",
"      <td>",
"       Vitamin A",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Xerosis (dry skin)",
"      </td>",
"      <td>",
"       Vitamin A",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ecchymosis",
"      </td>",
"      <td>",
"       Vitamin C or K",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Intradermal petechia",
"      </td>",
"      <td>",
"       Vitamin C or K",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Erythema (especially where exposed to sunlight)",
"      </td>",
"      <td>",
"       Niacin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hyperpigmentation",
"      </td>",
"      <td>",
"       Niacin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Seborrheic dermatitis (nose, eyebrows, eyes)",
"      </td>",
"      <td>",
"       Vitamin B2, Vitamin B6, Niacin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Scrotal dermatitis",
"      </td>",
"      <td>",
"       Niacin, Vitamin B2, Vitamin B6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       Eyes",
"      </td>",
"      <td>",
"       Angular palpebritis",
"      </td>",
"      <td>",
"       Vitamin B2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Corneal revascularization",
"      </td>",
"      <td>",
"       Vitamin B2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bitot's spots",
"      </td>",
"      <td>",
"       Vitamin A",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Conjunctival xerosis, keratomalacia",
"      </td>",
"      <td>",
"       Vitamin A",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"6\">",
"       Mouth",
"      </td>",
"      <td>",
"       Angular stomatitis",
"      </td>",
"      <td>",
"       Vitamin B12, Vitamin B2, Vitamin B6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Atrophic papillae",
"      </td>",
"      <td>",
"       Niacin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bleeding gums",
"      </td>",
"      <td>",
"       Vitamin C",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cheilosis",
"      </td>",
"      <td>",
"       Vitamin B2, Vitamin B6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Glossitis",
"      </td>",
"      <td>",
"       Niacin, folate, vitamin B12, Vitamin B2, Vitamin B6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Magenta tongue",
"      </td>",
"      <td>",
"       Vitamin B2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Extremities",
"      </td>",
"      <td>",
"       Genu valgum or varum, metaphyseal widening",
"      </td>",
"      <td>",
"       Vitamin D",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Loss of deep tendon reflexes of the lower extremities",
"      </td>",
"      <td>",
"       Vitamins B1 and B12",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Vitamin B1: thiamine; Vitamin B2: riboflavin; Vitamin B3: niacin; Vitamin B6: pyridoxine; Vitamin B12: cyanocobalamin.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Bernard MA, Jacobs DO, Rombeau JL. Nutrition and Metabolic Support of Hospitalized Patients. WB Saunders, Philadelphia 1986.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_19_1341=[""].join("\n");
var outline_f1_19_1341=null;
var title_f1_19_1342="Pleural fluid after lung transplant";
var content_f1_19_1342=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Changes in pleural fluid composition after lung transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 228px; background-image: url(data:image/gif;base64,R0lGODlh0QHkAOYAAP///4CAgAAAAEBAQMDAwCAgIDAwMHBwcLCwsBAQEKCgoFBQUODg4PDw8JCQkAAzmZC5nCBzOViWa8jcztDQ0P8AAP/w8P8QEMDN5v8wMEBmsy58Rf9AQP/AwOTu56zLtXSohGBgYP+wsICZzP9gYP9wcPL38zyFUv/Q0P+AgP/g4P+goEqNXv+QkNDZ7PDz+bDA3yBNpnCNxuDm8xBAn6Cz2f8gIDBZrFBzuWCAv5Cm00d2m9bl257CqbrUwmafd4KwkP9QUIBZjBxrRRhjUYyxqICslp0yGL9shkJ9dn8ZTI8WQhJXYx1bdd+2w8TV2qtrVfFXU9UVCh8she4jKXykorrDsqsrFYApXB5vPyVYk/Hn48C81u8DCQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADRAeQAAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+TgBBSDDQoBCg2C6uzugggBDgyD9Pbl+/ydDQQEBjFwEACBQIIG361rpzBeQ4a5KAQQMGCQAYoCDAi6OCCjoAMZEyS4B9KAyHv9UqqUFEKAAEEMRF48ACBmgpkbMWoEwNEjT526OlKcJ2ABgAUCECAoejRpAwEJADgQcOBp1Kk0V2rdimipy48CHABIIKABSLFkGyw1ilQp07Zr/5smxEVgKICJAe4KCIBXb4C6FQEDBjCYMN/Df7kq5kYAMd+ADRJMfAmgY0DLlisLaLzXb1+8nzvnKhyab2e8gwUPLdwY8YC8i2NfC/AaccAFGr9qvrw5s+XSwE+LpmsXK4Czxs9S8Lh2uca4h/jKnk5NuiGX2F+2/Ulh+0UKycOGdzA+4lQDBBowEFCAQAEBDNa3f3/vPQKkCgDYx4/IOvX/zvhHCEB1bQaAAkUtVcCBCbJXE3vuwSdfhPFBSF8uQrkUkALvFZDfgR1+SMFFCWQ1IlRZRQcbgCwqI+B1lB1HlgHoyJhRjRyy92GOHgrC44fivNjikMMISSQlRh6p5P8uSS75SJNORjkLlFIqQmWVWK5yZZaFbMnll6N4CaaYYJbZCZlcomnmmpeoiaWbbMYZCZxS0innnYvY6aSeePbZ5Yp+3gVooIRKwqeShxZ6Z6IstvaaopBCwiiAjg6KiQgiRJqmpXhOCoAIF5RggaZVesqipz5YwUEGKJAapakAevrBCQC0UEELri4J63+mnvABAChkwMGouQ5J22OBmjqrIBaUcEGmxZ5aW0B+wurrIKCKGi2vnC7a7SXLDmLBqq1uK9uu1O16LSG24mruYuhOt2u4hAQ77LtcxXvut5isS0izz+Krlb6xoUtvIdkSKzA/BMPLb7+/HjIuqwsz/PD/PvA4IA88EAGQD0oe1wOyIfEebEi7FZfT8DIN9JSAOz3tVNJJx4U0Un8XXyJBxIjYq3DK36ysTF0aWRZXW1ZJRVXSxqk4ygS0KgIwtEB7I3QyLWdUQAh++ZUaRV9XZJhrOevMcyIJV93N1cg0EEIC7xnQQGlhhy1Ia4c9+nTUi0xcrtrZsH3MVHkhVQ9VNTvgnMdFLQ4dyWWb7QjKgGMjuDEIoneRAhNeuJ8A+X0O5J+lQP2Iz5Vbc/krCrSzANeRHEBWAbD9KMiJJd5OYoqQm7LzI1OnXl3kyxTgQEth0bKy6ZCkLTw0q7uymQEDHCC2LEJL0EMkfj//jJFq8VVj/00IHVRQOgttnP5D8qAi2V60KU/8JRNsYIIklHu/jJGTaViTTIizCU5+0pGdxCwnBVQFSKYHO+zNT2cQmATq9JcMIxHgHi3Jy1nGUpYNpuVoSQGhW9iSlFQ0wAEImNv4YnG1+t1PEsGj4DGOZZtBBMAABbiHb3pjoN8IxzR5Ac0PT0GgIq4QFmyTQAQp4TwZFqk2h6FWZQpQAHTskABXDE4Q4TdEU2QHO9dj4QPpZ79KdM+JwoDSYLwjgO6U8DvjiSPiNmgKx/BldEgcIwQvkT80+sJIr7uhALiGoAUoiEGGdFDnJGQhRs4HPuMQnAsvMUE/8oJ/ZBmkPGR3o4/MCP9HIfJRKEGkI1QM4JSorJ78VqFETMTQkrqI3iq+6JIw5nEVk7xUqH4Gy1rIch9q4sEE7meCCXhAEBOYAACEmcxjDsIDPYDAB0zQykycsZe+1KMxzDKA7sxFjJIAQgQi+IEI/AAAE4gACwAggQi4MwLbA0A53ymBXGaij9gEZzaQspkQGAUWlZKEDyIgAQCAIAIbAAAEIgAEdkZgAgMtqAcQqkweRLCamqhkPl/xy1k6YACNsSUrAioJhAJgAyyIAA/aqcx2guAHG/ABAHrA0ELY05rOotpGW9FRVSQFpAP4pwMn0c5yDrQHG4iAINrJgpQWdKFLJARGN9HEnaqip6n/eBvcQLdKSdD0BEplAVjP6dCWPrScBRWEM2+qiWtaFRVYRUUDkJK7rkaCB+4850LhuVR4+iCpxwSrEn+QVnZGtRP4fCsp4noKetQkAEfkqB6Tuj28qrSv7jyBTAHggR9kNp7oLOMnNKpYUTDWFLQTRFDt2oqpduKVpQ3FaUthoLuI1BUdZWsnqhrbM2mzGFtrQMsaqM9XuNYTbu3tJma72OxIsbiu0K0nEqvcNv22GAoI6jeh64rjjlZYvKxuJZhbiANAFm7t+951N8ED0Y4CYCsQLybIS4gEKGABIuFdgNa7CRAcdhQisIENWhBe+TqChs+txWYKsID4RSOuHnBv/yk6wIELpKDABrbStHLB4L1YDxbwgA3H2vcxfIgsEYz1ryo6QIIKkEAFGT4wf0cxlZEUQL+TOJF7xAIJCpBlAAsioE9mdjMij4wQjI3wC1OhghaToAMxztOMR0EBBvwjvZQwSQII8GFIvGd8ImTa0qCiNBwL4rQqZoUFUnABDug0ykie8ieKSKDISuKnIe0xe95jFLqtBmx/Fhve+KK3WSjZFRZYgYDjC+c464KWdrFEAj6KgK1BgmgE2JyfAwNoTgvaMYWeRZpfsYIM2ODCjRZULO2Ix0n0r7aOWE5F8DIexzWOOUxxWi0OHQsKWxjGUaavKD5qSEnY5yIXbGR9kv/CH9Hh7BYgAAEtUOBkYBtY2KlEpZkjUeXbHZkRuNvRKHFnot2hWM6bmKgzZ9HkCwQByvIVNqRvGwm9OXio0Ja2Ldbc5jeXVtieoMAA4HbKBNCbFeRVNy4SvWjlAhwAOjaeJQqEnQRsV7K5iPYuVlBhVCv24Vrm8sEfcYBW4/sWCt+Fr0tg7Y0+HM/3nkR6KGBE1tpC471osotb3suHT3oAlSbunbGYnZFfFd2dSHnOncUBePcc6Z54dYLnxIB1HMbkPIU6J3D+C35zgNGWfLhUtDsNgCsdGIq2Adid+HDHMgCymFBAJiPN3XwXg+MWxnDlHp7aygi1Ej8+5bYRrnX/TpxdGB0IwgVeTMEk0SMxMClf5M/HvsoDYMSMqG3MKVFXW4id68XQOQn+ljoLZscgAgwgALNyQCEbECiLCO5wMXEAoU+p8IaPwLqNoQI2N114RmJAQKZSEQ92MHkffEsIlT9CueTJuZaYdyxIygvQH2PNNsjA2oFGwygSAkFcu2IWf6jFri0iu8W2RLYFP31C4z73u09G2leg9211H1nvKMDNxN/DzZRfiFv0fobwbbf3C9anDCLQcfWXK0lCAfpXI2zkRgYBR3MkHhVIHheYCkB2AFN3S75weMuQeIvHc/bHKQRAFiEgHYV0SCuoSMq2SBXySARoWu8BFQIoKTfY/1/6Bg2i53QlGB1f5EmdZCM0IkqlREo9goRYRwoCR3ce+IG6Nw1e54MMmIOUsH6qdAkKQCLpd3K+cIDPYAEtIGD+FinyRktG1wgd0U2eZ4WaAILR0AIXQHqawnfUkoKYAB4X0Xde6AtAsIPVsAIXQIKK8nI81mWXUHVIkYZw5YaaYAIbEH/TUAIZsICd4oiTsIYXYXuSwE8JYnO+AAGAWA0kkAGu8nBz5RILgGWT8Dop1IbDAImSOA0ZQAKkInazgYmaIIrZYAEZUAJ1qIvchmwS92DCiAmymA0qcAHblyzH+Aghh4iuQHMogXnzcGLXqA/PRgy8mA0oEDCF+IyOAP9zjEhlZAEbrWdkNaNlM4iLh5CM2QAqdNgnPkdplnYJp2QJF9EZYUZmWCFm2+aOh9CN2SCIhCgnDyd181WO0VEiQ4QagWY3Y5M34ngJkKhM2kCJljgmFdkIxHZxkwAS2qZn9PCQe1E3gXY3oNaRlgABhZUNpUgoAnkgmJAhTvh82XE4NKEcuLYAtvZ3jmYMF8kNteiMTPIoDEA9riB8BNASIRCDFKIfzMZVzqZrxuCS3OCLwEiPLNkVYEQWQEkJH4kkomE7EGduZ4ki54YMQ7kNy9iMa4JgtxAA7YE8VUF7pweKw4CV3PCNZVgmcul5nAaSk9AZc8WQpTCTiNCW2yD/j94SS2iICSV0HIi5WF15CXzJDQaJkJdJMpF5CYt4ETzWh8XAmNugkXGimJiQip1HmsWQmdwQk2yimsa4DKa5DUUZl50ZNLvZki+5DVqpm+HIDLepDW9pJrQJPb3pm+Dgl4C5nKDAlDVXgMS5ARjpDY7pCB2wnR1ALBbAnVQoAimQAvPIDcnpap/pmscAm92wmY1QAfAJn5nSAfFZATYwKr5Yn1RontD5Cdk1cAaXheoplNYZDqjJCPAJACtQARwAAPTZoBlQAVDmZBYghuWpDedZCfk4C9THDOzZDbK5CAlqK7ZIn6fWZoJwARWwkZbTn6GwobLQobZZoOGQm4pQ/5+V6KAV0GYXEDAJqjIu2gn/KRLsR52bgAE64AKw8KFZ+YsiWgElYJ+j8qA62qA2IKHMwqJlF6Sc8Gq1pJeWgAE4QAM0kAM1MAOsUJzccJyJkKAcUAFBoKMZwGIupqA7WgIlYAP7uQ0ZGgnSWWdgigkuoANjGgNmiqaowKR9CY6HkKDLWAErQJ/xSQLEMobwGQQHGThc6gkAwYpPGAqDWqiHWgpqyg3ZqSvfInztMxCURz6tao2wuj6o4IAuYV/ZhAqh+gCGeqai8AG/+Q3uiSicohbIBhOr9z83gTiuh0A+0XqmEBkZMXCwVnemgAEjoAG6KgMw8AKfcALXaaA5Kv+sh0Bx1GJ8ZoF8ZSFC6sp8p4AgNdIA9zigp2Ct2HoD2sqtmuCr5RCiRHJ/kLcbqtV/RMcbnBGA/zccixVGm4dxs0CvD2Cv29ov31qjtngk/ipFmQGwmCGwBwtE5peYtJM3lRkmy2mtN/Cw90oJ+koOwdmv35KxERiBcrSTFkizo9lcXzSypuWiLwADMnCyNzACGCAJ3loObNoi4JNpYYEOLbggTfsgMgiDMEhErBaojYABQzsILoC1GICvAPACGKCkALC1XgsJPfuzD6ABQusIK0sOzom0Jlh0QliERAhKR2iWZhkkv/UAD0AI2Mq3DyADgoABaSsI2Jq1lXC2J6v/toiLCEVbDqfKLd4Ao47AqhpjeSGjjZk7g6pWCXzrtw/QtTnwACMAAISrAYYbuptwtjGQtmtrCB+wTsBQTD1wNp4QrOmyqaBAuWqIHa+XQOtIM+polZPwuYNwuAAwAw9AA6arqyMwAq3buJswAzWQA62LA0lKCP6CCxPwAUAgAUklASDAAhsAAbOYCQeau5NbmSkEr5vRj1cxZvEbkHvbt8erugDwuYQLuHwrvZ5AvdZLA9jrAiYDCzzgAy4JVizwAxDgA7s3AQcFAhOrCfy6L5aTnpFAH5tGGJ3GwZ9GNpZgvKk7tMobA82LugCAvKYAwDFAA0NQBWK7Ch4wAaKY/1InoEQfwAOM4AEQgFK2mwk2asGzgcGPYBwbrBqeppIg7Lmk+7wp/AA6AAMnCwMnPMKrMANFMARkir3+2wm0+70IJQFA0APDpLLka76b0LJCvBggATu11pM/uY2UwL99+7cPS8VV/MRdbAq+Mqg5cLIxgANCW7aU0L0uGb7+ZUycAMERIMGacLQOExtIEbLJJoNSeR9UOZVY16eRYDIYUAMygK00oLYwgKiLcMAQ8AM2zMA+oMOjwMM+nAlvG8mL8UV5YZbkpjtqKcfXsL2F4AIwcK00kLYyUANiO8Oi2E4bgMMTfAqxW77n+wiRuxWcvD+6uwkFjAgzgAE70ARMQP8EWRABRJAEZLxkscDIjlwJuDsw1zw82+DLhMADH5DA6sTAE/AEOvDHuirIXWtoPcwCP/wI6cvOw6kN9OIBCKzKEXDDDezKiPDJoby8pGzKrvDMaCwJFawS1ewi7bwJN6zMYvwBzewIwCzMxGzM0RXBI60IQazRHS0NGx0JCFzG/2utONC6N5ADOrDHr/zPAZ0IauzSBY0lYJvPgMzPhDwKFh3NhQDJ/RDTyADVvQDRojzRpaPSjTDLT/3StYknJa0Bw6wBxRzDnwDLAM0I0wykQx0o2zwCN/2wOs3T4HLGTL3O5BCYXOkqRa3POY3Si4zViDDQd71h1cLV2gC2bt3/umLt15hg1j+d0Xq71u+C2GPquqWMCUttCC0d2X4ioxUzA8EM1qM8AhFbyIDNLE6q1p3tft5DvREdyIMsCY49CE4NDlJtDLc9Di4AytgayDvdyXQNLIwaDrlNDMW9D0jK13HtCOg8AWm9NoatXm+FpG+92GR9CGYNBYPI2TIZ3URC2YpdzBRdCLF7BBmwBcTt3c1w3NPRs8I82pdtU1EgBekM3ZJtYKB9rcuL1IOQAVeAUhAQ4AIe4MlU4AZ+4BPg0EWi3szA3kqy268tyFxABSUwzwMe4N8rARq+4RzO4WD1TiAe4pnV4STO4UBw4QQedQxuzamWCLv9x1PQBUjw/7w0/ryhrAE4nuM6ruOtS8c+DrhasANCPuREXuRGgOIQsNLjteIc3eKN4AQXsARKgAVCUOVVzrVYnuVce93B4ODA4OVfIgIlkAIkwAFmvir1WQHCcuYkMJ7j2QLguaerdt9OXglx3gJuTuZnjuY4uudt7uZwDp6ER+d1jgp3nudlfuYR2udsPp5ybglg/grWyMuF/guHngKPvuSJMOnU4azEW+mqfQieLhsitJagbjFeSUKESc1dNJGEBkV2FOuyPuu0Xuu2fuu4nuu6vuu83uu+/uvAHuzCPuyn5BjUUhq80uqDRhuwPuzObkfF/uzSDmrNPu3PHu3WPu3Ynu3X3v/sx97qslEelI4LYlfuXGruiCDu0zG14z6X5/7uvYDuh8Du1JG3n07u8H5J+c4k32Lvb7Lvc67v8Q7whT3wBi/wCM/vigIQvcDwvODwuwDxuiDxo9GBp37xGJ/xGr/xHJ8MqqoL4QN3vvCnnLsKNAeoEYGNdU6s0+p50BfvOUkLNqmzpoAg+nczdU6uE49BCAuZIQAQJa8KJ98RnCgLaQF+oJ6xsYRDQT8l7PEanvoK6wFJuOAS/3CTqab0GEJFdnYLCmBe7zF4reCUutASBcARSd/yxEHzrVAYszD1Te8KIdbzjfYPotn1sRBIm+gLgfQenUn0EU8AcofzTk5xWI//PZkUAlHveWTRmtMHFXGPW6qI9x1f+ZZ/+Zif+Zq/+Zzf+Z6faiefHp8/+oNgk2JP+pZvGW7TGQSwAKckFhIREI2BDh9VPZGP+sqVGesRFQGQgh3BOcrHAC1hXuiB+3WesV9xQrjRGR2xHiTUYBZv/Bmm+w5iEhh4yxlRQm6zj6su/eLVESh0EQYBISCRF9AaFQAQAg7AZcnj/Y2WIQaQEAiCEbAx/GfW+Kfv/pV+EbcPCACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydixQCA56jpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNGs7P0NHS09TV1tfY2drb3N3e3+Dh4uPk5eSBADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sequential changes in pleural fluid&nbsp;red cell&nbsp;and white cell counts (per mm",
"    <sup>",
"     3",
"    </sup>",
"    ) and LDH concentration (IU/L) in six patients after lung transplantation. In addition to the progressive decline in LDH and cell counts, there were also reductions in the neutrophil&nbsp;proportions (89 down to 29 percent of total WBC) and total protein content (3.4 down to 2.1 g/dL) during this time period.",
"    <div class=\"footnotes\">",
"     RBC: red blood cell count; WBC: white blood cell count; LDH: lactate dehydrogenase.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_19_1342=[""].join("\n");
var outline_f1_19_1342=null;
var title_f1_19_1343="Aortogram showing aortic rupture with pseudoaneurysm";
var content_f1_19_1343=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aortogram showing aortic rupture with pseudoaneurysm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 266px; height: 374px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The aortogram, obtained following administration of contrast material into the aortic root, demonstrates a focal pseudoaneurysm (arrow) arising from the proximal descending aorta immediately distal to the origin of the left subclavian artery (small arrow). This traumatic tear of the aortic occurred during a motor vehicle accident.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_19_1343=[""].join("\n");
var outline_f1_19_1343=null;
